Deletion of PTP1B in cardiomyocytes alters cardiac metabolic signaling to protect against cardiomyopathy induced by a high-fat d

Deletion of PTP1B in cardiomyocytes alters cardiac metabolic signaling to protect against cardiomyopathy induced by a high-fat diet - PMC
Official websites use .gov
.gov
website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
lock
) or
means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Journal List
User Guide
PERMALINK
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
the contents by NLM or the National Institutes of Health.
Learn more:
PMC Disclaimer
PMC Copyright Notice
. Author manuscript; available in PMC: 2025 Sep 19.
Published in final edited form as:
Sci Signal. 2025 Jul 22;18(896):eadp6006. doi:
10.1126/scisignal.adp6006
Deletion of PTP1B in cardiomyocytes alters cardiac metabolic signaling to protect against cardiomyopathy induced by a high-fat diet
Yan Sun
Yan Sun
Department of Biomedical Research and Translational Medicine, Masonic Medical Research Institute, Utica, NY, 13501, USA.
Find articles by
Yan Sun
Abhishek Kumar Mishra
Abhishek Kumar Mishra
Department of Biomedical Research and Translational Medicine, Masonic Medical Research Institute, Utica, NY, 13501, USA.
Find articles by
Abhishek Kumar Mishra
Vasanth Chanrasekhar
Vasanth Chanrasekhar
Department of Medicine, Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA.
Find articles by
Vasanth Chanrasekhar
Michaela Door
Michaela Door
Department of Cell and Molecular Physiology, Loyola University Chicago Stritch School of Medicine: Maywood, IL, 60153, USA.
Find articles by
Michaela Door
Chase W Kessinger
Chase W Kessinger
Department of Biomedical Research and Translational Medicine, Masonic Medical Research Institute, Utica, NY, 13501, USA.
Find articles by
Chase W Kessinger
Bing Xu
Bing Xu
Department of Biomedical Research and Translational Medicine, Masonic Medical Research Institute, Utica, NY, 13501, USA.
Find articles by
Bing Xu
Peiyang Tang
Peiyang Tang
Department of Biomedical Research and Translational Medicine, Masonic Medical Research Institute, Utica, NY, 13501, USA.
Find articles by
Peiyang Tang
Yunan Gao
Yunan Gao
Department of Cardiology, The Fourth Affiliated Hospital of Harbin Medical University, 37 Yiyuan Street, Harbin, Heilongjiang 150001, China.
Find articles by
Yunan Gao
Sarah Kamli-Salino
Sarah Kamli-Salino
University of Aberdeen, School of Medicine, Medical Sciences and Nutrition, Institute of Medical Sciences, Aberdeen, AB24 3FX, UK.
Find articles by
Sarah Kamli-Salino
Katherine Nelson
Katherine Nelson
Department of Biomedical Research and Translational Medicine, Masonic Medical Research Institute, Utica, NY, 13501, USA.
Find articles by
Katherine Nelson
Mirela Delibegovic
Mirela Delibegovic
University of Aberdeen, School of Medicine, Medical Sciences and Nutrition, Institute of Medical Sciences, Aberdeen, AB24 3FX, UK.
Find articles by
Mirela Delibegovic
E Dale Abel
E Dale Abel
Fraternal Order of Eagles Diabetes Research Center and Department of Medicine, University of Iowa, Iowa City, IA, 52242, USA.
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA.
Find articles by
E Dale Abel
6,
Jonathan A Kirk
Jonathan A Kirk
Department of Cell and Molecular Physiology, Loyola University Chicago Stritch School of Medicine: Maywood, IL, 60153, USA.
Find articles by
Jonathan A Kirk
Maria I Kontaridis
Maria I Kontaridis
Department of Biomedical Research and Translational Medicine, Masonic Medical Research Institute, Utica, NY, 13501, USA.
Department of Medicine, Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.
Find articles by
Maria I Kontaridis
1,
2,
8,
Department of Biomedical Research and Translational Medicine, Masonic Medical Research Institute, Utica, NY, 13501, USA.
Department of Medicine, Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA.
Department of Cell and Molecular Physiology, Loyola University Chicago Stritch School of Medicine: Maywood, IL, 60153, USA.
Department of Cardiology, The Fourth Affiliated Hospital of Harbin Medical University, 37 Yiyuan Street, Harbin, Heilongjiang 150001, China.
University of Aberdeen, School of Medicine, Medical Sciences and Nutrition, Institute of Medical Sciences, Aberdeen, AB24 3FX, UK.
Fraternal Order of Eagles Diabetes Research Center and Department of Medicine, University of Iowa, Iowa City, IA, 52242, USA.
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.
Author contributions
Y.S. and M.I.K. designed the project; Y.S., A.K.M., V. C., M.M.D., C.W.K, B.X., P.T., Y.G., S.K.S., K.N. performed experiments; Y.S., A.K.M., C.K., B.X., M.D., J.A.K., and M.I.K analyzed the molecular data; M.M.D. and J.A.K. analyzed the mass spectrometry data; M.D. provided and conducted the PTP1B western analyses; E.D.A. provided the
αMHC
Cre
/+
mice; and Y.S., A.K.M., E.D.A., J.A.K., and M.I.K. wrote and edited the manuscript. All authors have read and agreed to the published version of the manuscript.
Corresponding author: Maria I. Kontaridis, Ph.D., Gordon K. Moe Professor and Chair, Biomedical Research and Translational Medicine, Masonic Medical Research Institute, 2150 Bleecker St, Utica, NY 13501
Issue date 2025 Jul 22.
PMC Copyright notice
PMCID: PMC12445919  NIHMSID: NIHMS2107418  PMID:
40694612
The publisher's version of this article is available at
Sci Signal
Abstract
Cardiomyocytes (CMs) normally use fatty acid oxidation (FAO) as their primary energy source. In response to pathological stress, the substrate preference of CMs switches from FAO to glucose metabolism, leading to the development of heart failure. Obesity increases this pathological risk of cardiovascular disease. We focused on protein tyrosine phosphatase 1B (PTP1B), an inhibitor of insulin signaling, the abundance and activity of which are increased in brain, muscle and adipose tissues in obese and/or diabetic animals and in obese human patients. We generated mice with cardiomyocyte-specific deficiency in PTP1B (
PTP1B
fl/fl
::αMHC
Cre
/+
) to investigate the cardiomyocyte-specific role of PTP1B in response to cardiac dysfunction induced by high-fat diet (HFD) feeding. Although no physiological or functional cardiac differences were observed at baseline,
PTP1B
fl/fl
::αMHC
Cre
/+
mice were protected against development of cardiac hypertrophy, mitochondrial dysfunction, and cardiac steatosis induced by HFD feeding. Metabolomics data revealed that hearts with cardiomyocyte-specific deletion of PTP1B had increased FAO and lipolysis but reduced glucose metabolism. Furthermore, phosphoproteomic analyses and mechanistic studies identified an axis involving the kinases PKM2 and AMPK downstream of PTP1B in the heart, which collectively acted to promote FAO and suppress lipogenesis. Together, these results suggest that cardiomyocyte-specific deletion of PTP1B prevents a substrate switch from FAO to glucose metabolism, protecting the heart against the development of HFD-induced cardiac hypertrophy and dysfunction.
Introduction
Obesity has reached epidemic proportions worldwide and continues to rise at an alarming rate. Projections from the World Health Organization suggest that 50% of the US will be classically defined as obese by the year 2030, with the most jeopardized demographic being children
. Obesity also increases the risk for developing multiple diseases, including type 2 diabetes, certain cancers, and cardiovascular disease (CVD)
. With regards to the latter, obesity mediates adverse effects on glucose and lipid levels, increases arterial blood pressure, induces inflammation, and reduces pulmonary function, characteristics that can lead to cardiac hypertrophy, dysfunction and/or heart failure if left untreated
. Unfortunately, despite knowing the contributing factors that lead to HFD-related CVD, the molecular mechanisms for how obesity and the consequent associated physiological changes directly lead to CVD remain poorly understood.
Cardiac metabolism is complex and involves hormonal regulation and activation of multiple downstream signaling pathways that control the balance between glucose and fatty acid utilization
. Under normal physiological conditions, 70–80% of the adenosine triphosphate (ATP) needed for metabolic function in the heart is derived from fatty acid oxidation (FAO), whereas the remainder is generated by carbohydrate metabolism
10
. However, there is a shift from FAO to glucose utilization during cardiac hypertrophic growth and pathological remodeling
In contrast, cardiac substrate metabolism switches to favor glucose metabolism over FAO in response to hemodynamic stress and pathological stimuli
11
. Specifically, in response to obesity and a high-fat diet (HFD), the heart undergoes alterations in energy metabolism, increasing fatty acid uptake and enhancing FAO as a result of increased supply of fatty acids
12
13
14
. This change in energy metabolism contributes to lipotoxic heart disease, which may increase the risk of heart failure. However, uncovering the mechanisms governing excess lipid accumulation and adverse sequelae in cardiomyocytes in response to HFD entails more comprehensive investigation.
Systemic metabolic substrate preference is largely under the control of the circulating hormone insulin. Indeed, insulin signaling is a critical modulator of the body’s ability to metabolize carbohydrates, lipids and proteins
15
and is integral in regulating homeostatic processes that control cellular proliferation
16
, differentiation
17
, and apoptosis
18
. In the presence of insulin, the insulin receptor (IR) phosphorylates insulin receptor substrate (IRS) proteins, inducing the activation of critical downstream pathways
17
. These include modulation of the phosphatidylinositol 3-kinase (PI3K)–protein kinase B/AKT (AKT) pathway, which mediates the metabolic actions of insulin, and the Ras–mitogen-activated protein kinase (MAPK) pathway, which regulates gene transcription and cooperates with the PI3K pathway to regulate cell growth and differentiation
19
21
PTPN1
encodes the non-transmembrane protein tyrosine phosphatase non-receptor type 1 (PTP1B), a ubiquitously expressed protein that inhibits insulin signaling by directly dephosphorylating IRS-1.
22
24
25
. PTP1B is therefore considered an emerging potential therapeutic target against the development of obesity, insulin resistance, and diabetes. Indeed, obesity or diabetes is associated with increased PTP1B levels and activity in the brain, muscle and adipose tissues in animals
26
30
and human obese patients
26
31
33
. Conversely, mice with germline deletion of PTP1B are resistant to obesity and have increased insulin sensitivity induced by a HFD
34
. Although liver-specific or adipose-specific deletion of PTP1B does not affect weight gain in HFD-fed mice, they protect against the induction of obesity-induced ER stress
23
35
, suggesting a non-autonomous regulation of metabolism and/or obesity by PTP1B. Similarly, mice with neuronal-specific or pro-opiomelanocortin (POMC)-specific PTP1B deletion exhibit decreased body weight gain in response to HFD feeding, effects associated with increased leptin sensitivity and improved glucose homeostasis
36
37
In addition to IRS-1, PTP1B dephosphorylates and activates pyruvate kinase muscle isozyme 2 (PKM2) in pancreatic cancer cells and cultured adipocytes, inducing glycolysis by promoting the conversion of phosphoenolpyruvate to pyruvate
35
38
. Activated PKM2 also affects the adenosine monophosphate (AMP)/ATP ratio by inhibiting AMP-activated protein kinase (AMPK) activity
38
39
, thereby potentially controlling metabolic and cellular energy homeostasis by blocking FAO
40
41
and increasing lipogenesis
42
. Additionally, AMPK controls the expression of nicotinamide phosphoribosyl-transferase (NAMPT)
43
, the rate-limiting enzyme in the nicotinamide adenine dinucleotide (NAD) salvage biosynthesis pathway that is responsible for converting nicotinamide (NAM) to nicotinamide ribonucleotide (NMN)
44
. This PKM2/AMPK axis may be regulated by PTP1B, but how and whether this is modulated specifically in the heart remains unknown.
Given the complexities of PTP1B in both insulin/AKT and PKM2/AMPK signaling, it is critical to determine the direct role of PTP1B in the heart. Increased PTP1B activity is associated with increased incidence of heart failure in both rats and humans
45
. Genome wide expression analysis studies demonstrate that increased pressure overload in the heart increases the expression of PTP1B
45
. Both cardiac contractile and intracellular Ca
2+
signaling dysfunction are also associated with elevated expression levels of PTP1B
46
. Conversely, endothelial cell-specific deletion of PTP1B protects against pressure overload-induced heart failure by driving the activation of vascular endothelial growth factor (VEGF) signaling and angiogenesis, inducing migration and proliferation of microvascular endothelial cells, reducing hypoxia, and preventing fibrosis
47
48
We believe PTP1B is an integral signaling protein involved in metabolism and a nodal enzyme critical for the regulation of cardiac function. However, a direct role for PTP1B in cardiac insulin resistance in cardiomyocytes (CMs) and its effect on HFD-induced pathological cardiac remodeling remains unknown. Here, we leveraged a global and integrated metabolomics and phosphoproteomics approach to directly investigate the role PTP1B in CMs in response to a HFD, to assess whether deletion of this enzyme in the heart may protect against the development of HFD-induced cardiomyopathy.
Results
Generation of cardiomyocyte-specific PTP1B knock-out mice.
To investigate the role of PTP1B in HFD-induced cardiomyopathy, we generated mice with CM-specific deletion of
PTP1B
. We crossed
PTP1B
fl/fl
mice
36
with mice expressing Cre recombinase under the control of the
α-MHC
promoter to generate
PTP1B
fl/fl
::αMHC
Cre
/+
mice, as well as their background controls,
PTP1B
+/+
::αMHC
Cre
/+
mice (
Figure S1A
). PTP1B protein was undetectable in CMs isolated from
PTP1B
fl/fl
: αMHC
Cre
/+
mice but was detected in CMs from male and female
PTP1B
+/+
::αMHC
Cre
/+
mice. PTP1B expression in other cardiac cell types and/or in other tissues, including the spleen, remained unchanged (
Figure S1, C
). Male and female
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
:: αMHC
Cre
/+
mice were born at expected mendelian ratios (
Table S11
).
Cardiomyocyte-specific deletion of PTP1B prevents HFD-induced cardiomyopathy.
In
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
:: αMHC
Cre
/+
mice fed a normal diet (ND), hearts were of similar size and weight for both males and females and for either genotype (
Figure 1A
1B
S2A
S2B
), suggesting that PTP1B has minimal physiological effects on the heart at baseline. After 10 weeks of high fat diet (HFD) feeding in male control
PTP1B
+/+
::αMHC
Cre
/+
mice, we found that PTP1B abundance increased in response to HFD (
Figure S1F
). Consequently, control hearts developed hypertrophy with a 1.2 fold change in heart weight to tibia length, whereas hearts from
PTP1B
fl/fl
::αMHC
Cre
/+
mice remained normal, suggesting that deletion of PTP1B in CMs protects against HFD-induced cardiac hypertrophy in males (
Figure 1A
1B
).
Figure 1. CM-specific deletion of PTP1B prevents HFD-induced cardiomyopathy.
Open in a new tab
A.
Representative photographs of hearts from male
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
::αMHC
Cre
/+
mice maintained on a normal diet (ND) or high-fat diet (HFD) for 10 weeks. Scale bar, 50 mm.
. Heart weight to tibia length ratios from male control or
PTP1B
fl/fl
::αMHC
Cre
/+
mice fed a ND or HFD. N= 8–12 mice/group. *p<0.05 and **p<0.01 by two-way ANOVA with Bonferroni post-hoc test.
. Representative H&E whole heart cross-sections from
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
::αMHC
Cre
/+
male mice maintained on ND or HFD for 10 weeks. Scale bars, 1mm (upper) or 50μm (lower). N=5 mice/group.
. Wheat germ agglutinin (WGA) staining (red) of heart cross-sections from control and
PTP1B
fl/fl
::αMHC
Cre
/+
male mice fed a ND or HFD for 10 weeks. Scale bar, 50μm.
. Frequency distribution of CM area from control or
PTP1B
fl/fl
::αMHC
Cre
/+
hearts from male mice fed a ND or HFD for 10 weeks. N=4 mice/group, with at least 1×10
cell counts per heart. Data are presented as means ± SEM. * p<0.05, by Student’s
-test.
. Representative photomicrograph of ventricular myocytes isolated from
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
::αMHC
Cre
/+
male mice fed a ND or HFD for 10 weeks. Scale bar= 50 μm. N=4–6 mice/group. 200 cells were quantified per mouse.
Female mice have reduced metabolic and inflammatory effects, particularly as mediated by HFD-induced stress
49
52
, resulting in milder cardiovascular remodeling phenotypes as compared to males at similar time points
53
56
. Therefore, to better modulate the potential sex-specific effects of cardiac-specific PTP1B deletion in these mice, we extended our timeline and conducted experiments with female mice after 20 weeks of HFD feeding, as compared to just 10 weeks of HFD feeding in male mice. However, even at this later time point, we did not observe any overt phenotypic changes in heart size or weight in female mice in response to HFD in either genotype (
Figure S2A
S2B
), suggesting that female mice may be more physiologically cardio-protected against HFD-induced hypertrophy as has been previously suggested
53
57
Nonetheless, we found that HFD feeding increased overall CM cell size, induced myocardial disarray and resulted in enlarged nuclei in both male and female control
PTP1B
+/+
::αMHC
Cre
/+
mice (
Figure 1C
S2C
). In contrast, deletion of PTP1B in hearts isolated from both male and female HFD-fed mice showed near normal myocardial size and structure (
Figure 1C
S2C
) as compared to control mice, suggesting that deletion of PTP1B protects hearts against development of HFD-induced hypertrophy. Cardiac fibrosis or collagen deposition did not differ between
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
:: αMHC
Cre
/+
mice from either sex, whether they were fed a ND or HFD (
Figure S3A
). HFD feeding increased the mRNA expression of the inflammatory cytokines
IL-1β
and
IL6
in
PTP1B
+/+
::αMHC
Cre
/+
hearts but not in
PTP1B
fl/fl
::αMHC
Cre
/+
hearts (
Figure S3C
). To directly ascertain the effects of PTP1B on cardiac hypertrophy, we isolated individual CMs and found that HFD significantly enlarged the length, width, and overall area of CMs from HFD-fed
PTP1B
+/+
::αMHC
Cre
/+
control mice, as compared to ND-fed mice (
Figure 1F
S2F
Table S1
, and
Table S12
). In contrast, CMs from HFD-fed mice with cardiac-specific PTP1B deletion had normal length, width, and overall area, similar to those of CMs from mice fed a ND.
Echocardiographic analysis software that measures multilayer global longitudinal strain (GLS) can identify early abnormalities of myocardial dysfunction
58
59
. Therefore, to begin to assess the functional effects of HFD on cardiac-specific PTP1B deletion, we measured left ventricular wall peak longitudinal strain, strain rate, wall velocity and cardiac speckle tracking displacement in
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
:: αMHC
Cre
/+
male and female mice after 8 weeks of HFD feeding (
Table S2
Table S13
). Even at this early stage, both endocardial and epicardial speckle tracking parameters were higher in HFD-fed
PTP1B
fl/fl
::αMHC
Cre
/+
mouse hearts, indicating preservation of cardiac function. Specifically, male HFD-fed
PTP1B
fl/fl
::αMHC
Cre
/+
mice exhibited a normal range for endocardial GLS, whereas HFD-fed
PTP1B
+/+
::αMHC
Cre
/+
hearts had a lower value (
Table S2
). Similarly, epicardial GLS was also preserved in
PTP1B
fl/fl
::αMHC
Cre
/+
mice as compared to
PTP1B
+/+
::αMHC
Cre
/+
mice (
Table S2
). In addition, cardiac deformation, as reflected by strain and peak velocity rates, was higher in male HFD-fed
PTP1B
fl/fl
::αMHC
Cre
/+
mice than in HFD-fed
PTP1B
+/+
::αMHC
Cre
/+
control mice (
Table S2
). Female mice exhibited similar but less pronounced trends, such that HFD-fed PTP1B deleted hearts had greater endocardial and epicardial GLS as compared to HFD-fed control mice (
Table S13
). HFD-fed
PTP1B
fl/fl
::αMHC
Cre
/+
female mice also showed significantly preserved endocardial GLS rates, but no notable differences in epicardial GLS rates, peak velocity, or displacement measurements (
Table S13
). Together, these data suggest that deletion of PTP1B may be functionally cardioprotective against the cardiac stress associated with a HFD.
To evaluate the functional and structural changes over time in response to HFD, we utilized conventional echocardiography and measured cardiac functional parameters following 8, 10, or 12 weeks of ND or HFD in
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
::αMHC
Cre
/+
mice. We did not observe any significant differences in M-mode at 8 weeks of HFD feeding, despite the changes in GLS measurements. This was not unexpected because early HFD feeding does not typically result in overt functional changes using M-mode echocardiography in mice
60
61
. However, we began to see significant cardioprotective effects of PTP1B deletion in hearts starting as early as 10 weeks on HFD, including normalization of left ventricular mass, end-diastolic internal dimensions of the left ventricle (LVIDd), and posterior wall thickness in both systole (LVPWs) and diastole (LVPWd), results that were further confirmed after 12 weeks on HFD (
Figure 2A
Table S3
Data File S1
).
Figure 2. CM-specific PTP1B deletion preserves cardiac function in response to HFD.
Open in a new tab
. Representative echocardiography of
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
::αMHC
Cre
/+
male mice fed a ND or HFD for up to 12 weeks. Two-headed arrows indicate left ventricular chamber size or left ventricular wall thickness. LVIDd, left ventricular internal diameter in end diastole. LVPWd, left ventricular posterior wall thickness in diastole.
B and C.
Quantification of LVPWd (B) and LVIDd (C) (N=10–15 mice/group).
D.
Real-time q-PCR analysis of the expression of hypertrophy-related genes (
MYH6
MYH7
, and
ANP
) in CMs from
PTP1B
+/+
::αMHC
Cre
/+
or
PTP1B
fl/fl
::αMHC
Cre
/+
male mice maintained on a ND or HFD for 10 weeks. Gene expression was normalized to
18S
and
Eef1
(which encodes eukaryotic elongation factor-1) mRNAs. N=6–7 mouse hearts/group and each sample was assessed in technical triplicate. Data in graphs are presented as means ± SEM. *p<0.05, ** p<0.01, ***p<0.001 by ANOVA with Bonferroni post-hoc test.
With respect to female mice, we similarly observed significant cardioprotective effects in
PTP1B
fl/fl
::αMHC
Cre
/+
mice after 20 weeks of HFD feeding, as compared to control HFD-fed mice, including normalization of LVID in both systole (LVIDs) and diastole (LVIDd), normalization of left ventricular anterior wall thicknesses in both systole (LVPWs) and diastole (LVAWd), and normalization of LVPW in systole (LVPWs) (
Figure S4A
Table S14
Data File S1
).
To validate the echocardiographic data at the molecular level, we next assessed changes in fetal gene mRNA expression profiles in mice fed a HFD. We observed a significant increase in the expression of
ANP
(which encodes atrial natriuretic factor) and a switch from
MYH6
(which encodes αMHC) to
MYH7
(which encodes β-myosin heavy chain) in CMs from male
PTP1B
+/+
::αMHC
Cre
/+
, but not in those from
PTP1B
fl/fl
::αMHC
Cre
/+
mice fed HFD for 10 weeks (
Figure 2F
). However, no significant changes in the fetal gene expression program were detected in CMs isolated from either control or
PTP1B
fl/fl
::αMHC
Cre
/+
female mice, even after 20 weeks of HFD feeding (
Figure S4G
).
In this regard, female mice may be more protected against development of HFD-associated cardiomyopathy due to increased levels of estrogen
53
56
. To determine if aged female mice progressed and developed more severe HFD-associated heart pathologies later, mirroring the effects observed in male mice at an earlier time point, we continued HFD feeding in
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
::αMHC
Cre
/+
mice for 50 weeks. In this cohort, we found that the LVAW and LVPW thicknesses were all elevated, whereas LVID chamber dimensions were significantly decreased in both systole and diastole in the HFD-fed
PTP1B
+/+
::αMHC
Cre
/+
control mice, as compared to ND-fed control female aged mice. Moreover,
PTP1B
fl/fl
::αMHC
Cre
/+
aged female mice were protected against HFD-induced cardiac dysfunction, showing normalized cardiac functional parameters that were similar to those in ND-fed control female aged mice (
Table S15
). Together, these data suggest that deletion of PTP1B in CMs attenuates and protects both male and female mice against the development of HFD-induced cardiomyopathy.
Cardiomyocyte-specific deletion of PTP1B mitigates HFD-induced mitochondrial dysfunction.
Mitochondrial dysfunction is a pathogenic hallmark of HFD- and obesity-induced cardiomyopathy
62
63
. TEM showed no differences in mitochondrial ultrastructure between the
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
::αMHC
Cre
/+
hearts under conditions of ND (
Figure 3A
). In contrast, we observed disrupted mitochondrial ultrastructure, in which a subset of interfibrillar mitochondria was significantly swollen with disorganized and reduced cristae density in HFD-fed
PTP1B
+/+
::αMHC
Cre
/+
hearts (
Figure 3A
). These changes were not observed in HFD-fed
PTP1B
fl/fl
::αMHC
Cre
/+
hearts, where mitochondrial integrity appeared normal and preserved (
Figure 3A
). Additionally, the mitochondrial number did not vary between HFD-fed
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
::αMHC
Cre
/+
hearts (
Figure S5A
).
Figure 3. CM-specific deletion of PTP1B preserves mitochondrial function in the presence of HFD.
Open in a new tab
. Representative TEM images of cardiac mitochondria from male
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
::αMHC
Cre
/+
mice fed a ND or HFD for 10 weeks. Scale bars, 2 μm (upper) or 500 μm (lower). N=5 sections from 3 mice per group.
. Quantitive assessment of mitochondrial swelling from male
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
::αMHC
Cre
/+
mice fed a HFD for 10 weeks, based on the number of swollen mitochondria as a percentage of total mitochondria per field (N=3 hearts/group, with quantification from at least 5 TEM sections per heart).
C.
Real-time qPCR analysis of
SOD
(which encodes superoxide dismutase) and
CAT
(which encodes catalase) in CMs. Gene expression was normalized to
18S
and
Eef1
mRNAs. N=7–9 mouse hearts/group and each sample was assessed in technical triplicate. Data in graphs are presented as means ± SEM. *p<0.05, **p<0.01, ***p<0.001 by 2-way ANOVA with Bonferroni post-hoc test.
D.
Oxygen consumption rates (OCR) measured in mitochondria from the hearts of
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
::αMHC
Cre
/+
mice fed a ND or HFD for 10 weeks. OCR was measured after the sequential addition of the complex V inhibitor oligomycin (Oligo), the protonophore FCCP, and the complex III inhibitor antimycin A (AntiA) to analyze ATP-linked respiration, proton leak respiration, maximal respiratory capacity, mitochondrial reserve capacity, and non-mitochondrial respiration. Data are presented as means ± SEM. *p<0.05 by two-way ANOVA with Bonferroni post-hoc correction.
E and F
. Representative Western blots of hearts from male
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
::αMHC
Cre
/+
mice fed a HFD for 10 weeks using an antibody cocktail that recognizes the five mitochondrial oxidative phosphorylation complexes (E). Quantification of the abundance of OXPHOS mitochondrial complexes (F). *p<0.05, one-way ANOVA with Bonferroni post-hoc test.
. Representative image of JC-1 fluorescence in adult CMs from male
PTP1B
+/+
::αMHC
Cre
/+
or
PTP1B
fl/fl
::αMHC
Cre
/+
mice fed a HFD for 10 weeks. Red fluorescence indicates the JC-I mitochondrial aggregate, whereas green fluorescence indicates monomeric JC-1. Scale bar, 50 μm.
H.
Quantificative assessment of the red to green fluorescence intensity ratio indicating changes in mitochondrial membrane potential (N = 6 mice/group). *p<0.05 by one-way ANOVA with Bonferroni post-hoc test.
A potential mechanism by which HFD is thought to mediate cardiac dysfunction is through increased generation of reactive oxygen species (ROS) and therefore oxidative stress
64
. Inhibiting PTP1B reduces oxidative stress in response to HFD feeding
65
66
. To determine if CM-specific deletion of PTP1B provides a similar antioxidant effect, we measured the mRNA expression of
SOD
(which encodes superoxide dismutase) and
CAT
(which encodes catalase), two enzymes that protect cells against ROS. We observed a significant increase in both
SOD
and
CAT
in CMs isolated from HFD-fed
PTP1B
fl/fl
::αMHC
Cre
/+
mice as compared to CMs from
PTP1B
+/+
::αMHC
Cre
/+
control mice (
Figure 3C
). These data suggest that CM-specific deletion of PTP1B could mediate an antioxidant effect against development of HFD-induced cardiomyopathy. Moreover, the upregulation of SOD and CAT expression may also be an adaptive response to maintaining cellular homeostasis in response to HFD in the
PTP1B
fl/fl
::αMHC
Cre
/+
mouse hearts.
Next, we examined the effect of CM-specific PTP1B deletion on the respiratory activity of mitochondria. Basal mitochondrial oxygen consumption rates (OCR) were similar between
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
::αMHC
Cre
/+
mitochondria fed a ND from both male and female mouse hearts (
Figure 3D
). Moreover, OCR was similar between ND-fed
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
::αMHC
Cre
/+
mitochondria in the presence of the ATP synthase inhibitor oligomycin, the mitochondrial oxidative phosphorylation uncoupler FCCP, and after treatment with rotenone and antimycin (
Figure 3D
). In contrast, OCR was significantly impaired in HFD-fed
PTP1B
+/+
::αMHC
Cre
/+
mitochondria, with reduced overall baseline levels of respiration, but was not affected in HFD-fed
PTP1B
fl/fl
::αMHC
Cre
/+
mitochondria. These results suggest that deletion of PTP1B in CMs protects against HFD-induced mitochondrial dysfunction in both male and female mouse hearts (
Figure 3D
).
Next, we examined the protein levels of electron transport chain (ETC) complexes. We observed comparable levels of all OXPHOS complexes in both male and female ND-fed
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
::αMHC
Cre
/+
hearts (
Figure 3E
S5B
). However, in response to HFD, the abundance of NADH:ubiquinone oxidoreductase subunit B8 (NDUFB8; complex I) and succinate dehydrogenase subunit b (SDHB; complex II) were significantly increased in
PTP1B
fl/fl
::αMHC
Cre
/+
mouse hearts, raising the possibility of increased flux through complex I (
Figure 3E
S5B
).
To evaluate the mitochondrial membrane potential, we used JC-1 to stain CMs isolated from HFD-fed
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
::αMHC
Cre
/+
mice. We found that
PTP1B
fl/fl
::αMHC
Cre
/+
CMs had active and hyperpolarized mitochondria as compared to those from
PTP1B
+/+
::αMHC
Cre
/+
CMs, confirming that the depletion of PTP1B in CMs prevents HFD-induced mitochondrial dysfunction (
Figure 3G
). Together, these results indicate that CM-specific deletion of PTP1B preserves mitochondrial function and structural integrity following HFD.
Cardiac-specific deletion of PTP1B shifts cardiac metabolism from glycolysis to fatty acid oxidation.
To better characterize the metabolic phenotype of CM-specific deletion of PTP1B, we analyzed the cardiac tissue metabolome of HFD-fed
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
::αMHC
Cre
/+
mice. Our resulting dataset identified a total of 741 metabolites (
Table S16
), 86 of which significantly differed between control and
PTP1B
fl/fl
::αMHC
Cre
/+
hearts. Indeed, many of these metabolites affect critical metabolic signaling pathways, as analyzed with MetaboAnalyst
67
Figure 4A
Tables S4
S8
). Specifically, levels of metabolites central to glycolysis, such as glucose 6-phosphate, fructose 6-phosphate, fructose 1,6-bisphosphate, were decreased in both male and female
PTP1B
fl/fl
::αMHC
Cre
/+
mouse hearts (
Table S4
). Moreover, HFD-fed
PTP1B
fl/fl
::αMHC
Cre
/+
mouse hearts exhibited decreased TCA cycle intermediates (
Table S5
). Given these results, we measured the activity of pyruvate dehydrogenase (PDH), an enzyme that catalyzes pyruvate into acetyl-CoA, the rate-limiting step for glucose oxidation
68
70
. In HFD-fed
PTP1B
fl/fl
::αMHC
Cre
/+
mouse hearts, PDH phosphorylation was increased, indicative of decreased PDH activity (
Figure 4B
S6A
).
Figure 4. Metabolomics analysis reveals increased triglyceride mobilization and fatty acid oxidation in hearts from male
PTP1B
fl/fl
::
αMHC
Cre
/+
mice.
Open in a new tab
A.
Enrichment analysis of metabolomics data from whole hearts from
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
::αMHC
Cre
/+
mice fed a HFD was performed using MetaboAnalyst. N=4 mice/group.
B-C.
Representative Western blots (B) and quantification of PDH phosphorylated at Ser
293
(C) in heart lysates. n=6–7 mice/group.
D.
Oil Red O staining for lipid droplets in heart sections from male
PTP1B
+/+
::αMHC
Cre
/+
or
PTP1B
fl/fl
::αMHC
Cre
/+
mice fed a ND or HFD for 10 weeks. Scale bar, 50 μm. N=4 mice/group.
E and F
. Real-time PCR analysis of
SREBP
(E) and
HSL
(F) in CMs from
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
::αMHC
Cre
/+
mice fed a ND or HFD. Gene expression was normalized to
18S
and
Eef1
mRNAs. N=7–9 mice/group and each sample was assessed in technical triplicate.
G-H
. Representative Western blots (G) and quantification of HSL phosphorylation (H) in heart lysates from
PTP1B
+/+
::αMHC
Cre
/+
or
PTP1B
fl/fl
::αMHC
Cre
/+
mice fed a HFD for 10-weeks. n=6–7 mice/group.
I-L
. Gene expression of
PPARα
(I)
, CPT1b
(J),
ACADVL
(K), and
HADHB
(L) in CMs from
PTP1B
+/+
::αMHC
Cre
/+
or
PTP1B
fl/fl
::αMHC
Cre
/+
mice. Gene expression was normalized to
18S
and
Eef1
mRNAs. N=7–9 mice/group and each sample was assessed in technical triplicate. Data in graphs are presented as means ± SEM. *p<0.05, ** p<0.01, ***p<0.001 by 2-way ANOVA with Bonferroni post-hoc test.
Next, we asked if fat utilization was altered in
PTP1B
fl/fl
::αMHC
Cre
/+
hearts. Oil red O staining showed that ND feeding did not lead to lipid accumulation in
PTP1B
+/+
::αMHC
Cre
/+
or
PTP1B
fl/fl
::αMHC
Cre
/+
mouse hearts. In contrast, HFD feeding promoted lipid accumulation in
PTP1B
+/+
::αMHC
Cre
/+
hearts, but not in
PTP1B
fl/fl
::αMHC
Cre
/+
hearts (
Figure 4D
S6C
). To evaluate the effects of PTP1B on myocardial lipid metabolism, we measured the expression of lipogenic genes by quantitative real-time polymerase chain reaction (qRT-PCR) analysis. The expression of
SREBP1c
(which encodes sterol regulatory element binding protein c) was significantly decreased in
PTP1B
fl/fl
::αMHC
Cre
/+
hearts, as compared to
PTP1B
+/+
::αMHC
Cre
/+
controls, irrespective of whether the mice were fed a normal diet or HFD (
Figure 4E
S6D
). SREBP modulates cardiac lipid metabolism and its dysregulation is implicated in cardiovascular diseases. Specifically, inhibiting
SREBP
in the heart reduces cardiac lipid accumulation, as well as decreases mitochondrial and endoplasmic reticulum stress
71
. Moreover, elevated
SREBP1
levels are observed in heart tissues from diabetic patients, which is positively correlated with their myocardial dysfunction
72
. Therefore, the decrease in
SREBP
levels in the heart resulting from CM-specific deletion of PTP1B suggests decreased lipid accumulation and improved myocardial function in response to HFD in these mice.
In addition to changes in
SREBP
levels, we also observed significantly reduced phospholipid and lysophospholipid metabolic intermediates in both male and female
PTP1B
fl/fl
::αMHC
Cre
/+
hearts (
Table S6
S7
). Moreover, the mRNA abundance and phosphorylation of the key enzyme hormone-sensitive lipase (HSL), which mediates triglyceride hydrolysis, was increased in HFD-fed
PTP1B
fl/fl
::αMHC
Cre
/+
hearts (
Figure 4F
S6E
), which paralleled the reduced lipid droplet accumulation in the cardiac tissues in these mice. FAO metabolites, such as acylcarnitines (AC), were also significantly increased in both male and female HFD-fed
PTP1B
fl/fl
::αMHC
Cre
/+
mouse hearts (
Table S8
). ACs arise from the conjugation of acyl-coenzyme A with carnitine for the transport of long-chain fatty acids across the inner mitochondrial membrane for β-oxidation.
To further validate these findings, we measured for changes in fatty oxidation in HFD-fed
PTP1B
fl/fl
::αMHC
Cre
/+
mice. We measured the expression of key FAO-related transcripts by qRT-PCR analysis, which showed increased expression of
PPARα
, which encodes peroxisome proliferator activated receptor α (a nuclear hormone receptor that regulates the oxidation and transport of fatty acids
73
74
) in HFD-fed
PTP1B
fl/fl
::αMHC
Cre
/+
hearts as compared to HFD-control hearts (
Figure 4I
). Further, CM-specific deletion of PTP1B increased the expression of
CPT1b
(which encodes carnitine palmitoyl-transferase 1b, a mitochondrial long chain fatty acyl importer), in response to both ND and HFD feeding (
Figure 4J
S6H
).
ACADVL
, which encodes acyl-CoA dehydrogenase very long chain (the protein that catalyzes the first step of the mitochondrial beta oxidation pathway), was also elevated in HFD-fed
PTP1B
fl/fl
::αMHC
Cre
/+
mice (
Figure 4K
S6I
). Similarly, the expression of
HADHB
(which encodes acetyl-CoA acyltransferase) was increased in
PTP1B
fl/fl
::αMHC
Cre
/+
mouse hearts in response to both ND and HFD feeding (
Figure 4L
S6J
). Further, primary CMs isolated from control HFD-fed male mice showed significantly decreased dependency on glucose and an increased dependency on FAO when in the presence of the PTP1B inhibitor DPM1001 (
Figure S7A
). Together, these data suggest that PTP1B acts as a molecular switch such that CM-specific PTP1B deletion increases cardiac FAO and decreases both lipogenesis and glucose utilization.
To confirm the metabolic impact of HFD treatment, we assessed levels of circulating insulin and triglycerides in ND- and HFD-fed male
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
:: αMHC
Cre
/+
mice. Although no changes were observed in response to ND, HFD-fed
PTP1B
+/+
::αMHC
Cre
/+
mice had increased levels of both insulin and triglyceride, as compared to HFD-fed
PTP1B
fl/fl
:: αMHC
Cre
/+
mice (
Figure S7C
), suggesting that CM-specific deletion of PTP1B is protective against the development of HFD-mediated metabolic dysregulation.
Phosphoproteomic analyses show PTP1B deletion in CMs protects against pathological changes in multiple downstream cardiac signaling pathways in response to HFD feeding.
Tyrosine phosphorylation specifically controls multiple, critical cellular processes including growth, differentiation, survival, and metabolism. It is a reversible and dynamic process, whereby the phosphorylation state is governed by opposing actions of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs)
75
. Given that PTP1B modulates multiple receptor tyrosine kinase signaling pathways, including VEGF, PI3K/AKT, and Ras/MAPK signaling (
Figure S8
25
35
38
76
, we next sought to determine the downstream signaling effects of PTP1B deletion in hearts from HFD-fed mice. We conducted a phosphotyrosyl (pY)-specific proteomics screen in hearts from
PTP1B
+/+
::αMHC
Cre
/+
or
PTP1B
fl/fl
::αMHC
Cre
/+
mice fed HFD for 10 weeks and identified a total of 1970 unique pY peptides. Of these, 267 were differentially phosphorylated proteins (DPPs) that showed either significantly increased (97.35%) or decreased phosphorylation (2.65%) (
Figure 5A
). Specifically, the phosphorylation of PDH was increased 2.4 fold in HFD-fed
PTP1B
fl/fl
::αMHC
Cre
/+
mouse hearts, validating our previous molecular metabolomics profile data on this enzyme (
Fig 4B
). We also performed a functional enrichment analysis for the differentially phosphorylated proteins (DPPs) through KEGG pathway analysis
77
, which identified a total of 11 significantly enriched pY pathways in PTP1B-deleted hearts, including VEGF, hypertrophic cardiomyopathy (HCM), cAMP, autophagy, diabetic cardiomyopathy, and PI3K-AKT signaling pathways (
Figure 5B
).
Figure 5. Loss of PTP1B in CMs induces the phosphorylation of ERK, AKT, PKM2 and AMPK.
Open in a new tab
. Volcano plot of the average pY phosphoproteomics data for male
PTP1B
fl/fl
::αMHC
Cre
/+
and
PTP1B
+/+
::αMHC
Cre
/+
hearts (n=5 mice/group). Volcano plots are depicted as the fold change of each phophosite. The grey dotted lines indicate the p<0.05 cutoff (calculated from Welch’s t-test).
B.
The heat map of differentially phosphorylated proteins in key KEGG pathways.
C-D.
Representative Western blots (C) and quantification of. acetyl CoA carboxylase 1 (ACC1) phosphorylation (D) in cardiac lysates from male
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
::αMHC
Cre
/+
mice fed a HFD for 10 weeks. N=6–8 biological replicates per group.
E-G.
Representative Western blots (E) and quantification of the phosphorylation of IR (F) or VEGFR (G) in cardiac lysates from male
PTP1B
+/+
::αMHC
Cre
/+
or
PTP1B
fl/fl
::αMHC
Cre
/+
mice fed a ND or HFD and injected with saline or insulin (10 mU/g i.p.) for 10 minutes.
H-I
. Representative Western blot (H) and quantification of phosphorylated NFAT (I) in cardiac lysates from male
PTP1B
+/+
::αMHC
Cre
/+
or
PTP1B
fl/fl
::αMHC
Cre
/+
mice fed a HFD for 10 weeks.
J-L.
Representative Western blot (J) and quantification of the phosphorylation of ERK (K) or AKT (L) in cardiac lysates from male
PTP1B
+/+
::αMHC
Cre
/+
or
PTP1B
fl/fl
::αMHC
Cre
/+
mice fed a ND or HFD for 10 weeks.
M-O.
Gene expression of
BAX
(M) and
BCL2
(N) and ratio of
BCL2
to
BAX
(O) in CMs from
PTP1B
+/+
::αMHC
Cre
/+
or
PTP1B
fl/fl
::αMHC
Cre
/+
fed a ND or HFD for 10 weeks. Gene expression was normalized to
18S
and
Eef1
mRNAs. N=7–9 mice per group and each sample was assessed in technical triplicate.
P-R.
Representative Western blots (P) and quantification of mTOR phosphorylated at Ser
248
(Q) and the ratio of LC3II to LC3I (R) in cardiac lysates from male
PTP1B
+/+
::αMHC
Cre
/+
or
PTP1B
fl/fl
::αMHC
Cre
/+
mice fed a ND or HFD for 10 weeks.
S-U
. Representative Western blots (S) and quantification of PKM2 phosphorylated at Tyr
105
(T) and AMPK phosphorylated at Thr
172
(U) in cardiac lysates from male
PTP1B
+/+
::αMHC
Cre
/+
or
PTP1B
fl/fl
::αMHC
Cre
/+
mice fed a ND or HFD for 10 weeks. For (C) to (U), N=6–8 hearts/group. Data are presented as means ± SEM. *p<0.05, ** p<0.01, ***p<0.001 by 2-way ANOVA with Bonferroni post-hoc test.
We next sought to validate the phosphoproteomic analysis to better understand the molecular mechanisms underlying the metabolic shift in HFD-fed PTP1B-deleted hearts. KEGG analysis of showed an enrichment for cyclic AMP (cAMP), a pivotal second messenger enzyme involved in the regulation of glycogen, sugar, and lipid metabolism, in
PTP1B
fl/fl
::αMHC
Cre
/+
hearts (
Table S17
). The cAMP-dependent protein kinase A (PKA) was also hyperphosphorylated in
PTP1B
fl/fl
::αMHC
Cre
/+
hearts, along with the protein phosphatase 1 (PP1) regulatory subunits 12A and 12B (PPP1R12A and PPP1R12B) and its catalytic subunit, PP1β (PPP1CB) (
Table S17
). Similarly, we found that phosphorylation of acetyl CoA carboxylase 1 (ACC1), the enzyme that catalyzes the conversion of acetyl coenzyme A to malonyl coenzyme A, was increased in
PTP1B
fl/fl
::αMHC
Cre
/+
hearts. ACC1 is the rate-limiting enzyme in lipogenesis
78
; as a downstream regulator of PKA, ACC1 hyper-phosphorylation in PTP1B deleted hearts suggested attenuation of fatty acid synthesis (
Table S18
). Increased ACC1 phosphorylation was further validated by Western blotting analysis of hearts from HFD-fed
PTP1B
fl/fl
::αMHC
Cre
/+
mice and from control mice (
Figure 5C
). Together with the reduced
SREBP
mRNA expression levels and the decreased amounts of phospholipids and lysophospholipid metabolites in
PTP1B
fl/fl
::αMHC
Cre
/+
hearts (
Fig 4E
Tables S6
S7
), these data suggest that CM-specific PTP1B deletion prevents lipogenesis.
Because PTP1B inhibits IR and VEGFR signaling
79
80
81
, we measured the effect of intraperitoneally injected insulin on IR or VEGFR phosphorylation in
PTP1B
+/+
::αMHC
Cre
/+
or
PTP1B
fl/fl
::αMHC
Cre
/+
mice. Although we did not observe significant differences at baseline, hearts isolated from
PTP1B
fl/fl
::αMHC
Cre
/+
mice fed either a ND or HFD exhibited increased insulin-induced activation of both IR and VEGFR as compared to insulin-stimulated control mouse hearts (
Figure 5E
).
Vascular endothelial growth factor (VEGF) and insulin activate multiple integral downstream signaling pathways, including Ras/MAPK, AKT, PKC, and Ca
2+
-calcineurin signaling
82
83
. To assess how PTP1B regulation of IR and VEGFR signaling modulates downstream pathway activation, we conducted KEGG analysis of hearts from HFD-fed
PTP1B
fl/fl
::αMHC
Cre
/+
mice and
PTP1B
+/+
::αMHC
Cre
/+
control mice. We found that
PTP1B
fl/fl
::αMHC
Cre
/+
hearts showed hyperphosphorylation of nuclear factor of activated T cells (NFAT) (
Figure 5H
), a downstream effector of both VEGF and cardiac hypertrophy signaling pathways (
Figure S7
Table S18
S19
). Normally found in a hyper-phosphorylated inactive state in the cytosol, NFAT dephosphorylation is required for nuclear translocation and for the induction of genes that modulate cardiac hypertrophy
84
. Therefore, increased phosphorylation of NFAT in PTP1B-deleted CMs suggested that these mice were protected against cardiac hypertrophy in response to HFD, validating our phenotypic, echocardiographic, and fetal gene expression data (
Figure 1A
2A
Table S2
S3
).
To further understand the effects of cardiac-specific PTP1B deletion on these pathways, we measured changes in the phosphorylation of ERK, a downstream effector of Ras/MAPK signaling through VEGFR. Hearts isolated from both male and female
PTP1B
fl/fl
::αMHC
Cre
/+
mice fed either a ND or HFD showed significant increases in phosphorylated ERK (
Figure 5J
S9A
). We next assessed the effects of PTP1B deletion on the PI3K/AKT signaling pathway. Similarly, we found that both male and female
PTP1B
fl/fl
::αMHC
Cre
/+
mouse hearts had significantly increased levels of AKT phosphorylation in response to both ND and HFD feeding (
Figure 5J
5L
S9A
S9C
).
AKT can modulate apoptosis and autophagy. Moreover, HFD increases apoptosis and reduces autophagy, although the underlying mechanisms remain unclear
85
. In this regard, the B-cell leukemia/lymphoma 2 (BCL-2) protein is an important regulator of cell death and apoptosis
86
. To maintain cardiac homeostasis, BCL-2-associated athanogene 3 protein (BAG3) binds to BCL-2 to prevent its degradation, thereby inhibiting apoptosis
87
. Our proteomics data showed that the phosphorylation of BAG3 was significantly increased in
PTP1B
fl/fl
::αMHC
Cre
/+
hearts (
Table S20
), suggesting PTP1B may prevent apoptosis by preserving BCL2 degradation
88
90
. To validate this notion, we measured the expression of mRNA encoding various apoptosis regulators, including of B-cell lymphoma 2 (BCL2) and BCL associated X (BAX)
91
. Although we did not see any overt effects on
BAX
expression (
Figure 5M
),
BCL2
expression was significantly increased (
Figure 5N
). Moreover, we found that the ratio of BCL2 to BAX (BCL2/BAX), a measurement of apoptosis, was increased in CMs from HFD-fed
PTP1B
fl/fl
::αMHC
Cre
/+
mice (
Figure 5O
). Together, these data suggest that CM-specific deletion of PTP1B protects against apoptosis in response to HFD.
Because AKT-dependent enhancement of protein synthesis is also mediated in part by its downstream activation of mammalian target of rapamycin (mTOR), we next sought to determine the effects of CM-specific PTP1B deletion on autophagy. mTOR phosphorylation was increased in hearts from control HFD-fed
PTP1B
+/+
::αMHC
Cre
/+
mice, but not in those from
PTP1B
fl/fl
::αMHC
Cre
/+
mice (
Figure 5P
S9A
S9D
), despite the upstream increase in AKT in these mice (
Figure 5J
5L
S9A
S9C
). This decrease in mTOR activity was validated by measuring autophagy, which was enhanced in hearts from HFD-fed
PTP1B
fl/fl
::αMHC
Cre
/+
mice, as evidenced by an increase in LC3B-II-to LC3B-I ratios (
Figure 5P
5R
S9A
S9E
).
HFD induces mTOR activity in both the liver and skeletal muscle, leading to impaired insulin signaling
92
. The reduction in HFD-induced mTOR activity by deletion of PTP1B in CMs suggests a cardio-protective role against HFD-induced insulin resistance. However, the mechanism for how this occurs remains unclear, particularly given the increase in the phosphorylation of the upstream regulator of mTOR, AKT. It is possible that a parallel signaling pathway differentially modulates mTOR and autophagy in response to HFD feeding in mice with a CM-specific deletion of PTP1B. In this regard, PKM2, a rate-limiting glycolytic enzyme, is dephosphorylated and activated by PTP1B in both pancreatic cancer cells and cultured adipocytes
35
38
Figure S8
). To assess whether CM-specific PTP1B affects this pathway, we examined the phosphorylation status of PKM2, which was significantly elevated only in hearts from HFD-fed
PTP1B
fl/fl
::αMHC
Cre
/+
mice (
Figure 5S
S9F
), suggesting decreased PKM2 activity in response to PTP1B deletion. PKM2 normally inhibits AMPK activity
93
, and concomitantly, we found that AMPK phosphorylation was significantly increased in
PTP1B
fl/fl
::αMHC
Cre
/+
hearts, even in those from mice fed a ND (
Figure 5S
5U
S9F
S9H
). Together, these results suggest that the absence of PTP1B in CMs improves insulin resistance and HFD-associated cardiomyopathy by increasing AMPK activity in the heart.
PTP1B differentially regulates NAD
to modulate cardiac metabolic functions in response to HFD.
Our data suggested that HFD feeding altered metabolic signaling profiles in
PTP1B
fl/fl
::αMHC
Cre
/+
mice. AMPK can mediate NAD
metabolism by activating nicotinamide phosphoribosyltransferase (NAMPT), a key energy sensing enzyme that regulates NAD
synthesis, thereby increasing cellular NAD
levels and influencing the activity of NAD
-dependent enzymes
94
. We hypothesized that CM-specific deletion of PTP1B protects against impaired HFD-induced cardiomyopathy by activating the NAD
biosynthesis pathway downstream of the PKM2/AMPK signaling axis. We first measured changes in NAD
metabolic intermediates, which showed increased levels of nicotinamide ribonucleotide (NMN) only in male
PTP1B
fl/fl
::αMHC
Cre
/+
hearts (
Table S9
), suggesting that NAM is converting to NMN, and that deletion of PTP1B in CMs is activating NAD+ biosynthesis through this pathway. However, hearts from both male and female
PTP1B
fl/fl
::αMHC
Cre
/+
mice had diminished amounts of nicotinamide (NAM) metabolites (
Table S9
). To validate the role for NAM metabolites in the regulation of PTP1B in the heart, we measured the levels of NAD
, NADH, NADP
, and NADPH directly in the heart. We found that all NAD
intermediates were increased in CM-specific deleted PTP1B hearts (
Figure 6A
). Next, we measured the expression of genes related to NAD
synthesis. The expression of
NAMPT
NMNAT
NAPRT
, and
NADSYN
were all significantly higher in hearts from both male and female
PTP1B
fl/fl
::αMHC
Cre
/+
mice in response to ND or HFD feeding (
Figure 6B
S10
). Moreover, NAMPT protein abundance was also elevated in hearts isolated from
PTP1B
fl/fl
::αMHC
Cre
/+
mice (
Figure 6C
). Together, these results suggest that CM-specific deletion of PTP1B promotes NAD
biosynthesis by regulating metabolic processes in cardiac mitochondria and AMPK-modulated metabolic signaling pathways.
Figure 6. NAD
production is increased in male
PTP1B
fl/fl
::αMHC
Cre
/+
mice.
Open in a new tab
. Levels of cardiac NAD
, NADH, NADP
and NADPH were evaluated in male
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
::αMHC
Cre
/+
mice fed a ND or HFD for 10 weeks. N=7–9 mice/group, and each sample was assessed in technical triplicate.
B.
NAMPT
NMNAT
NAPRT
and NADSYN
were measured by quantitative real-time PCR in CMs from
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
::αMHC
Cre
/+
mice fed a ND or HFD for 10 weeks. Gene expression was normalized to
18S
and
Eef1
mRNAs. N=7–9 mice/group and each sample was assessed in technical triplicate.
C-D
. Representative Western blots (C) and quantification of NAMPT normalized to the loading control GAPDH (D) in hearts from
PTP1B
+/+
::αMHC
Cre
/+
and
PTP1B
fl/fl
::αMHC
Cre
/+
mice fed a ND or HFD for 10 weeks. N=6–8 hearts/group.
E-G.
Representative Western blots (E) and quantification of the phosphorylation of PKM2 (F) or AMPK (G) in CMs from HFD-fed male
PTP1B
+/+
::αMHC
Cre
/+
control mice treated with DMSO, DPM1001 or Compound 3000 (Comp.3K). N=3 mouse hearts/group.
H.
Real-time qPCR analysis of the expression of
MYH7, ANP
BNP
, and
CPT1b
in CMs from male HFD-fed
PTP1B
+/+
::αMHC
Cre
/+
or
PTP1B
fl/fl
::αMHC
Cre
/+
mice treated with DMSO or AMPK inhibitor (Comp.C). Gene expression was normalized to
18S
and
Eef1
mRNAs. N=6–7 mice/group and each sample was assessed in technical triplicate.
I-J.
Representative Western blot (I) and quantification of HSL phosphorylation (J) in Compound C-treated CMs from HFD-fed
PTP1B
+/+
::αMHC
Cre
/+
or
PTP1B
fl/fl
::αMHC
Cre
/+
mice. N=4 mice/group. Data in graphs are presented as means ± SEM. *p<0.05, ** p<0.01, ***p<0.001 by 2-way ANOVA with Bonferroni post-hoc test.
PTP1B deletion exerts cardioprotective effects through increased activation of the PKM2-AMPK signaling axis.
To confirm the role of PTP1B regulation on PKM2 in response to HFD, we performed pharmacological analysis on adult CMs from HFD-fed
PTP1B
+/+
::αMHC
Cre
/+
control mice. Treatment with either the PTP1B inhibitor DPM1001 or the PKM2 inhibitor Compound 3000 resulted in an increase in the phosphorylation of both PKM2 and AMPK (
Figure 6E
). To further validate the cardioprotective and cardiometabolic effects of PTP1B deletion in CMs, we sought to determine if inhibition of AMPK would reverse the cardioprotective effects of PTP1B deletion. Indeed,
PTP1B
fl/fl
::αMHC
Cre
/+
CMs treated with the AMPK inhibitor Compound C had fetal gene expression profiles similar to those from control HFD-fed
PTP1B
+/+
::αMHC
Cre
/+
hearts (
Figure 6H
). Moreover, treatment of
PTP1B
fl/fl
::αMHC
Cre
/+
with Compound C also decreased the mRNA expression of
CPT1b
Figure 6H
). Finally, Compound C also attenuated the increase in the phosphorylation of HSL in
PTP1B
fl/fl
::αMHC
Cre
/+
CMs (
Figure 6I
). Together, these data confirm that mice with CM-specific deletion of PTP1B are cardioprotected from HFD feeding through aberrant regulation of a PTP1B-PKM2-AMPK signaling axis, the effects of which mediate decreased lipogenesis and increased lipolysis, autophagy, FAO, and NAD
production (
Figure 7
).
Figure 7. PTP1B in the heart functions as a metabolic switch.
Open in a new tab
PTP1B deletion increases cardiac FAO and decreases both lipogenesis and glucose utilization. Mechanistically, PTP1B deletion inactivates PKM2, thereby increasing AMPK and autophagy and leading to activation of NAD
biosynthesis and cardioprotection from HFD feeding. Created in BioRender. Science, M. (2025)
Discussion
Using a HFD-induced cardiomyopathy mouse model, we observed that CM-specific deletion of PTP1B in mice ameliorated HFD-induced cardiomyopathy (specifically, hypertrophy) and diminished cardiac steatosis. CM-specific deletion of PTP1B activated VEGF/ERK and AKT signaling but decreased mTOR phosphorylation. The suppression of mTOR and subsequent increase in autophagic activity was regulated by a PTP1B-PKM2-AMPK axis in the heart. In addition, deletion of PTP1B in CMs altered lipid metabolism and mitochondrial function in response to HFD-induced cardiomyopathy, promoting increased FAO and decreased glycolysis in response to HFD. CM-specific deletion of PTP1B also promoted NAD
biosynthesis through AMPK-mediated metabolic signaling pathways (
Figure 7
S8
). Together, our data indicate that CM-specific deletion of PTP1B protects the heart against the development of HFD-induced cardiomyopathy by directly regulating cardiac metabolic signaling.
Patients with systolic dysfunction show increased PTP1B activity
45
. Conversely, germline deletion of PTP1B in mice improves cardiac output without affecting infarct size
95
. Moreover, miR-206, which directly inhibits PTP1B expression, can reduce CM apoptosis and myocardial infarct size in rats
96
. Although these data suggest a protective role for PTP1B in the heart, the underlying mechanisms have remained unclear. Several previous studies focused only on the molecular effects of PTP1B in cardiac endothelial cells. For example, overexpression of PTP1B in bovine aortic endothelial cells inhibits VEGF-induced AKT phosphorylation
97
. Conversely, deletion of PTP1B in endothelial cells protects against cardiac hypertrophy induced by transverse aortic constriction and improves cardiac VEGF signaling and angiogenesis
47
98
. Moreover, deletion of PTP1B in endothelial cells also promotes VEGF-induced ERK activation, increasing cell proliferation and migration
48
. Here, we showed that CM-specific deletion of PTP1B increased the phosphorylation of both IR and VEGFR, validating that these receptors are critical substrates for PTP1B in the heart
79
80
81
. Consequently, CM-specific deletion of PTP1B also led to increased downstream activity of ERK and AKT.
Activated ERK1/2 induces physiological hypertrophy, increases contractile force and reduces fibrosis
99
100
. Similarly, increased AKT activity protects against ischemia-reperfusion injury
101
. However, overt cardiac-specific overexpression of constitutively active AKT can also induce pathological cardiac hypertrophy in mice
102
103
, suggesting that dosage of AKT is critical to the modulation of cardiac hypertrophy. Together, ERK and/or AKT activation in the heart may potentially have positive therapeutic effects, by maintaining cardiac performance and preventing the transition to maladaptive hypertrophy and heart failure. However, the beneficial effects may depend on various factors, including whether the effects are acute or chronic and require further research. AKT also inhibits autophagy by activating mTOR, thereby leading to accumulation of damaged organelles, which can contribute to the development of cardiac dysfunction. Indeed, defects in autophagy and mitophagy are implicated in HFD-associated mitochondrial dysfunction in the heart
104
105
. In response to short-term HFD feeding, genetic ablation of
Atg7
, which encodes a critical autophagy factor, impairs mitophagy and leads to cardiac dysfunction
105
. In response to deletion of PTP1B, we observed increased AKT activity but decreased mTOR activity and increased autophagy, which may partially explain how PTP1B deletion may protect against HFD-induced cardiac hypertrophy and mitochondrial dysfunction. However, the regulation of mTOR and autophagy by PTP1B does not appear to be through the expected canonical pathways, but rather through a PTP1B-PKM2-AMPK axis. We showed that deletion of PTP1B decreased PKM2 activity, thereby protecting against pathological cardiac hypertrophy. Direct inhibition of PKM2 is also protective against development of right ventricular dysfunction in mice subjected to pulmonary artery banding
106
or with pulmonary hypertension
107
Mitochondrial dysfunction and energy imbalance are critical components of HFD-induced cardiomyopathy, which leads to increased reliance on glucose and decreased FAO
108
110
. With regards to glycolysis, we observed that deletion of PTP1B in CMs led to reduced steady-state levels of glycolytic intermediates and TCA intermediates, suggesting reduced activity or potentially increased metabolic flux. With regards to FAO, the directionality of the change in FAO in the heart is variable and model dependent. Thus, it might not be apparent if decreased FAO levels are causal to or a consequence of cardiac dysfunction in response to HFD feeding. For example, patients with heart failure with preserved ejection fraction (HFpEF) have reduced FAO
61
111
112
. In addition, multiomics analysis also found that patients with HCM had reduced levels of myocardial FAO intermediates, including decreased levels of acylcarnitine (AC) and reduced expression of
CPT1
, which encodes a critical regulator of mitochondrial long-chain FAO
113
115
. These studies suggest that increasing FAO could be beneficial in certain contexts. Conversely, increased FAO is associated with increased production of reactive oxygen species (ROS) in hearts from obese mice and rats
116
117
118
. In a physiological context, increased ROS induced by FAO could be self-limiting
119
and a short-term negative feedback mechanism as an adaptation to pathological stress imposed on the heart. As a result, the negative effects of ROS might not outweigh the positive benefits of enhanced FAO. However, considerations for therapeutic modulation of FAO in hypertrophy and heart failure remain to be determined.
Excessive accumulation of lipids is a cause of HFD-induced cardiomyopathy in the absence of underlying vascular disease
61
120
. Moreover, HFD induces an imbalance between lipid uptake and oxidation by affecting either increased lipogenesis or decreased FAO
121
123
. Here, we found that phospholipids and lysophopholipids, which are CVD risk factors in patients
124
125
, were reduced in response to CM-specific deletion of PTP1B. Phospholipid metabolism plays a critical role in cellular adaptation to changes in growth and hypertrophy
126
. Thus, reduced phospholipid levels in hearts from HFD-fed CM-specific deleted PTP1B mice may be a consequence of reduced hypertrophy (
Figure 2, A
Figure S4, A
, and
Table S6
). Moreover, although it remains unclear whether HFD-associated cardiomyopathy is a direct result of abnormal FAO or accumulation of toxic lipids or both, our finding that deletion of PTP1B in CMs increased cardiac FAO and lipolysis while decreasing lipogenesis indicates that PTP1B may be critical for regulating lipid metabolism in the heart. Increased FAO has been thought to contribute to HFD-associated cardiomyopathy but is now thought not to contribute to the development of cardiac dysfunction
61
111
112
. Specifically, increasing FAO by deletion of the gene encoding acetyl coenzyme A carboxylase 2 (ACC2) in the heart does not cause cardiac dysfunction in mice
111
. This likely means that cardiac lipotoxicity is not due to increased FAO per se, but rather to an imbalance of fatty acid supply, storage, and use. Similarly, in cardiometabolic HFpEF, cardiac dysfunction occurs due to accumulation of cardiac lipids and reduced FAO
112
Our findings suggested that increased FAO was critical to preserve cardiac function in response to HFD feeding. CM-specific deletion of PTP1B led to increases in FAO, levels of acylcarnitine, and mitochondrial respiration and decreased accumulation of toxic lipids in the heart. Moreover, deletion of PTP1B in CMs restored the OXPHOS complex by increasing the abundance mitochondrial complexes I and II of the ETC, thereby increasing ATP synthesis and decreasing free radical production
127
128
. A lower membrane potential (Δψ) may correlate with an increase in ROS production
129
130
, and we showed that Δψ was increased in
PTP1B
fl/fl
::αMHC
Cre
/+
CMs from mice fed a HFD, suggesting decreased ROS production and preserved mitochondrial integrity. Indeed, our gene expression profiling suggested that CM-specific deletion of PTP1B potentiated cardioprotective effects at the molecular level, even in the absence of a pathological stimulus such as HFD (
Fig. 4I
). Therefore, the cardiometabolic protective effects in our mice could help protect against and even mitigate future cardiac pathologies in response to stress. Along these lines, increased FAO does not always induce mitochondrial or cardiac dysfunction in non-obese mice. Specifically, under conditions of pressure overload, mice with a CM-specific deletion of
ACC2
have a substrate utilization profile similar to that of sham animals, with increased FAO and decreased glycolysis, thereby indicating a protective effect development of cardiac hypertrophy and fibrosis in response to pathological stress
131
There are several lines of evidence that CM-specific deletion of PTP1B leads to the activation of lipolysis and a higher utilization of FAO for CM energetics in response to HFD, including fewer neutral lipids, increased PKA signaling, increased phosphorylation of HSL, increased phosphorylation (and therefore deactivation) of ACC, higher
PPARα
and
Cpt1β
expression (
Figure 4, G
6, H
Table S5
S6
S19
S20
). Moreover, the decreased ACC activity as mediated by PTP1B inhibition led to increased Cpt1 activity and therefore to induction of FA synthesis (
Figure 4J
). Together, these data identify PTP1B as a mediator of an integral molecular switch in cardiac energetics. Consequently, it may be possible that the effects of PTP1B in the heart modulate more than just HFD-induced cardiac dysfunction; it may also be a nodal enzyme critical for the regulation of other cardiac-associated stress responses as well, including heart failure and metabolic cardiac diseases. CM-specific deletion of PTP1B maintained lower levels of circulating insulin and triglyceride, suggesting protection against HFD-mediated metabolic dysfunction (
Figure S7C
). Additional studies to prove this possibility for a therapeutic potential for PTP1B inhibition in the heart are needed to prove this point and are currently ongoing in the lab.
Nevertheless, due to its ability to promote FAO and lipolysis, PTP1B appears to be a promising therapeutic target to treat human obesity and type 2 diabetes. Indeed, the
PTP1B
gene is located within the chromosomal region of 20q13.1–13.2, a locus that is linked to the development of both obesity and type 2 diabetes
132
134
. Six single nucleotide polymorphisms for
PTP1B
have been identified in the French-Canadian population
132
135
. Further, genome-wide association studies have indicated that rare single nucleotide polymorphisms (SNPs) within the
PTP1B
gene correlate with the development of type 2 diabetes in Danish
136
and Canadian
137
populations and are also early predictors of insulin resistance in individuals of Italian descent
138
. As well, the SNP rs3787348 in
PTP1B
is associated with the effects of weight reduction therapy on BMI and waist circumference among obese Japanese patients
139
. Finally, four
PTP1B
SNPs in an obese population are predictors of dyslipidemia
140
CM-specific deletion of PTP1B promoted NAD
synthesis through its ability to enhance AMPK-mediated metabolic signaling and increase NMN levels (the NAD
precursor). NAD
is a central metabolite in the salvage pathway and is involved in energy and redox homeostasis. Stimulating NAD
synthesis protects against the development of both diabetic cardiomyopathy
141
and HFpEF
142
. Moreover, deletion of PTP1B led to increased abundance of
NAMPT
, which encodes the rate-limiting enzyme in the salvage pathway. CM-specific overexpression of NAMPT protects against the development of HFD-induced cardiac hypertrophy and diastolic dysfunction in mice
141
. Furthermore, NAMPT overexpression restores levels of NAD
and NADP
, protecting mice deficient in the mitochondrial complex I subunit NDUFS4 from developing diabetic cardiomyopathy
143
. Finally, systemic NAMPT overexpression protects mice against the development of angiotensin II-induced hypertension
144
. Here, we showed that increased NAD
signaling in
PTP1B
fl/fl
::αMHC
Cre
/+
hearts was mediated by the effects of deletion of PTP1B on PKM2 and AMPK, leading to elevated mitochondrial FAO
94
145
and increased phosphorylation of NAMPT
146
. In line with our findings, intraperitoneal injection of NMN stimulates NAD
biosynthesis in obese mice
147
, preventing the development of cardiac hypertrophy
148
. We observed increased levels of NMN in male
PTP1B
fl/fl
::αMHC
Cre
/+
hearts without concomitant increase in NR (
Table S9
). Instead, we observed increased NAMPT levels, suggesting that the mechanism of regulation by PTP1B deletion in CMs is mediated by increases in the NAM-->NMN-->NAD arm of the salvage pathway. However, it may also be possible that this can be achieved by blockade of the other arm of this pathway, which is NR-->NMN-->NAD. Future research will be needed to determine the precise mechanism and the translational application of NAD
, NMN, and its precursors in the prevention of diabetic cardiomyopathy.
Although our results suggested a protective cardiac effect in response to deletion of PTP1B in the heart, another paper suggested that CM-specific deletion of PTP1B in mice may be pathological, inducing a hypertrophic phenotype that is exacerbated by pressure overload
149
. Specifically, argonaute 2 (AGO2), a critical component of the RNA-induced silencing complex, is inactivated in response to CM-specific deletion of PTP1B, thereby preventing miR-208b-mediated inhibition mediator complex subunit 13 (MED13) and leading to thyroid hormone-mediated pathological cardiac hypertrophy. There could be several reasons why we and others
36
150
151
might have seemingly opposing results to this paper. First, inhibition of miR-208b improves rather than exacerbates cardiac dysfunction in titin-induced dilated cardiomyopathy
152
. Second, the upregulation of MED13 in the heart confers resistance to obesity, regulating systemic energy homeostasis and influencing cardiac metabolic processes that increase energy expenditure and improve insulin sensitivity
153
. Third, Coulis
et al
. used
PTP1B
fl/fl
mice as their control group instead of
αMHC
Cre
/+
mice, and the expression of the
αMHC-Cre
transgene by itself in some mouse strains can induce a cardiac phenotype, including hypertrophy
154
. Finally, it is possible that different pathological stimuli can lead to different outcomes. For example, overexpression of NAMPT can induce heart failure by activating Sirt1
155
in response to pressure overload or can reduce cardiac diastolic dysfunction, apoptosis and proinflammatory signaling by regulating NAD
, NADP
and NADPH production in response to HFD
141
Our data suggest potential sex-driven differences in the cardiometabolic alterations associated with HFD-related cardiomyopathy. It took longer for female mice to develop signs of cardiomyopathy in response to HFD feeding (20 weeks compared to 10 weeks for the males), irrespective of genetic background. In addition, hypertrophy in response to HFD was less pronounced in female mice. However, gene expression of the key metabolic enzymes involved in NAD
synthesis were elevated in both male and female
PTP1B
fl/fl
::αMHC
Cre
/+
mouse hearts, suggesting that the effects of pathological stress could have similar causes in both males and females.
Together, our results suggest that CM-specific deletion of PTP1B is protective against development of HFD-induced cardiomyopathy. Deletion of PTP1B in CMs mediates a substrate switch from glucose metabolism to FAO, protecting hearts against the development of HFD-induced cardiac hypertrophy and dysfunction. These protective effects are mediated by a PTP1B/PKM2/AMPK axis that is critical for the regulation of NAMPT and NAD
biosynthesis.
Materials and methods
Mice
To generate mice with cardiomyocyte-specific PTP1B knock-out (
PTP1B
fl/fl
::αMHC
Cre
/+
), C57Bl6J mice with loxP-flanked PTP1B floxed alleles (
PTP1B
fl/fl
) (courtesy of Benjamin G. Neel, NYU Grossman School of Medicine, Laura and Isaac Perlmutter Cancer Center, New York
and purchased from the Mutant Mouse Resource and Research Center (MMRRC) at The Jackson Laboratory, an NIH-funded strain repository [B6;129S4-
Ptpn1
tm2Bbk
/Mmjax, RRID:MMRRC_032243-JAX]
36
were mated with transgenic mice that express Cre driven by the α myosin heavy chain (
MYH6
) promoter (
αMHC
Cre
/+
156
. Mice were weaned at Day 30 (4 weeks of age) and immediately placed on either normal diet (ND) (PicoLab Rodent Diet20#5053) or HFD (Research Diet #12492, 60 kcal% fat) at post-natal day 30, for a period of 10 weeks (males) or 20 weeks (females). Unless otherwise noted, endpoint analyses were conducted in 14- (males) or 24- (females) week old mice. Unlike males, which showed a significant cardiac phenotype by 10 weeks on HFD, female mice did show any overt phenotype in this same time course. Therefore, female mouse studies were conducted over a period of 20 weeks to reveal their phenotypes. All other experimental groups were age- and sex-matched mice. All mice were maintained on the C57Bl6J background and
αMHC
Cre
/+
mice were used as our control groups. All animal procedures were approved by the Masonic Medical Research Institute Animal Care and Use Committee. Our PHS assurance number is D16–00144(A3228–01) and we are an AAALAC (#001865) accredited institution.
RNA Extraction and Real-time PCR analysis
RNA was isolated using Trizol (Invitrogen) and purified with RNeasy kits (Qiagen). A total of 1 μg RNA was reverse-transcribed with Iscript Supermix (Bio-rad). The resulting cDNA was used to amplify the target genes by SYBR Green PCR Master Mix (Thermo Fisher Scientific). 18S ribosomal RNA
(18S),
eukaryotic translation elongation factor 1 (
EEF1A1
) and ribosomal protein L4 (
RPL4
) were used as control housekeeping genes. Data were quantified using the comparative C
method (ΔΔCT). For primer sequences and PCR conditions, see
Table S10
Biochemical Studies
Tissue lysates were prepared by homogenizing the tissue in radioimmunoprecipitation (RIPA) buffer (25 mmol/l Tris-HCl [pH 7.4], 150mmol/l NaCl, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, 5mmol/l EDTA), 1mmol/l sodium fluoride, 1mmol/l sodium orthovanadate, and a protease cocktail at 4°C, followed by sonication. For immunoblots, proteins were resolved by sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes. Immunoblots were performed with anti-PTP1B (Abcam), anti-AKT, anti-phospho-AKT (Ser
473
), anti-extracellular signal-regulated kinase (ERK) 1/2, anti-phospho-ERK 1/2 (Thr
202
/Tyr
204
), anti-AMPK, anti-phospho-AMPK (Thr
172
), anti- microtubule-associated protein 1A/1B light chain 3B (LC3B), anti-PKM2, anti-phospho-PKM2 (Tyr
105
), anti-ACC1, anti-phospho-ACC1 (Ser
79
) (Cell Signaling Technology) or anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Santa Cruz Biotechnology, Inc).
Histology
Hearts were isolated and fixed in 4% paraformaldehyde for 24 hours and paraffin embedded. Sections were stained with hematoxylin/eosin (H&E) or Masson’s trichrome and images were taken using a Keyence BXZ microscope. Cryosections (8 μm) of hearts were permeabilized with 0.1% Triton X in PBS for 5 mins at room temperature, hearts were blocked with normal horse serum for 30 mins. Coverslips were incubated with wheat germ agglutinin (WGA)-Alexa Fluor 647 (1:100) (Thermo Fisher Scientific) antibodies in a humidity chamber. Slides were imaged by a Zeiss Confocal microscope. The quantitative analysis of CM area size included 5 different fields from four mice per group and 3 sections per heart. The total number of myocytes counted was 1–2×10
cells per mouse.
Echocardiography and Speckle Tracking Analysis
Transthoracic echocardiography was conducted on non-anesthetized animals as described previously
, using a Visual Sonics Vevo 3100
high-frequency ultrasound rodent imaging system. Hearts were imaged in the two-dimensional parasternal short-axis view, and an M-mode echocardiogram of the mid ventricle was recorded at the level of papillary muscles. Heart rate, posterior wall thickness (LVPW), and end-diastolic and end-systolic internal dimensions of the left ventricle (LVIDd and LVIDs, respectively) were measured from the M-mode image.
Early-stage heart function was assessed using 2D speckle-tracking and quantitative myocardial deformation analysis using the Vevo Strain software (Vevo LAB v5.6.1). Three consecutive cardiac cycles from the long-axis B mode videos were chosen for analysis using the M mode setting, to limit respiratory artifacts in LV wall motion. Utilizing the Free Curve software tool, the borders of the endocardium and epicardium were determined and segmented into 6 regions. An initial execution of speckle tracking resulted in estimations of velocity, displacement, and strain rate for each segment. Wall motion tracking was also manually adjusted frame by frame. Peak systolic strain values were measured in each segment of the LV for the endocardial layer, mid-myocardial layer and epicardial layer.
Mitochondrial Respiration
Mitochondria were isolated from hearts as previously described
157
. Briefly, hearts were dissected and washed in ice-cold mitochondrial isolation buffer. Tissues were cut into small pieces and homogenized with a Potter-Elvehjem tissue grinder. Tissue pieces were disrupted with at least 30 strokes and then centrifuged at gradient speed to obtain a pellet. The pellet was resuspended in mitochondrial assay solution containing 1 mM pyruvate, 2 mM glutamine, 10 mM glucose, and 5 mM malate. Mitochondrial respiration was determined using an XF96 Extracellular Flux Analyzer (Seahorse Bioscience). For those measurements, 50μg mitochondria were plated and centrifuged at 2,000 g for 20 mins to promote adherence. Oligomycin (1μg/mL) and carbonyl cyanide-p-trifluoromethoxyphenyl-hydrazon (FCCP) (20mM) were used to inhibit ATP synthase. Rotenone and Antimycin (40mM) were used to inhibit complex I and complex III-dependent respiration. All readings were normalized to protein content.
The MitoFuel Seahorse assay was conducted using an XF96 Extracellular Flux Analyzer, as directed following the manufacturer’s protocol. Briefly, adult CMs from HFD-fed mice were isolated, plated onto 96-well Seahorse XF96 plates at 5,000 cells per well, and cultured for 6 hours with or without the PTP1B inhibitor DPM1001 (100nM). Prior to the assay, the culture media was replaced with DMEM base medium supplemented with 1 mM pyruvate, 2 mM glutamine, 10 mM glucose, and 200 μM BSA-palmitate. To inhibit the glucose oxidation pathway, the mitochondrial pyruvate carrier inhibitor UK5099 (2 μM) was used. The long-chain FAO pathway was inhibited using the carnitine palmitoyl transferase 1A inhibitor etomoxir (4 μM). Additionally, the glutamine oxidation pathway was blocked with the glutaminase inhibitor BPTES (3 μM).
Detection of Mitochondrial Membrane Potential
JC-1 (Abcam, USA) was used to assess the mitochondrial membrane potential. Isolated cardiomyocytes were incubated with 5μM JC-1 staining solution at 37 °C protected from the light for 10 min according to the manufacturer’s instruction. Adult cardiomyocytes were washed by culture medium and imaged by a Zeiss Confocal microscope. JC1 monomers and aggregates were both excited at 488 nm. Detection of fluorescence for JC1 monomers and aggregates were performed respectively at 530 and 590 nm. Cells with high mitochondrial membrane potential (Δψ) promote the formation of red fluorescent JC-1 aggregates, whereas cells with low Δψ exhibit green fluorescence
158
. Ratio F(aggregate)/F(monomer) was subsequently evaluated using Image J
Transmission Electron Microscopy (TEM)
TEM studies were performed by the SUNY Upstate University Transmission Electron Microscopy Center. Briefly, mice were sacrificed and their hearts were perfused with 2.5% (vol/vol) glutaraldehyde in 0.1M Na-cacodylate buffer (pH 7.4). The hearts were immediately cut into pieces < 1mm
and fixed in 2.5% (vol/vol) glutaraldehyde in 0.1M Na-cacodylate buffer (pH 7.4) for 2 hours. After fixation with 1% osmium tetroxide in 0.1M cacodylate buffer, the tissue was dehydrated in a graded series of ethanol washes and then embedded in Spurr’s resin. Semithin (0.5μm) and ultrathin (90nm) sections were cut, mounted on copper grids, and stained with uranyl acetate and lead citrate. Sections were viewed with a JEM 2100F transmission electron microscope.
Adult Primary Cardiomyocyte Isolation
Mice were injected with intraperitoneal heparin (40 units/mice), and their hearts were collected, isolated and perfused through the aorta. The perfusion buffer consisted of KCl (14.7mM), NaCl (120.4mM), KH
PO
(0.6mM), Na
HPO
(0.6mM), MgSO
7H
O (1.2mM), 2,3 butanedione monoxime (10mM), taurine (30mM), HEPES (10mM), and glucose (5.5mM). The heart was digested with collagenase II digestion buffer (2 mg/ml) for approximately 8–10 min. The heart was cut from the cannula and placed in the dish with digestion buffer and stopping buffer (12.5μM CaCl
and 10% exosome depleted FBS in perfusion buffer). Isolated cardiomyocytes were cultured in a six well plate (treated with laminin), with myocyte culture medium (ScienCell #6201), 5% exosome depleted FBS, and 1% penicillin/streptomycin.
Phospho-proteomics Analysis
Whole heart pieces from
PTP1B
fl/fl
::αMHC
Cre
/+
and control mice were homogenized in 9M Urea with 0.3% Triton X-100 and protease and phosphatase inhibitor cocktails (Thermo Fisher Scientific, Halt). Samples were centrifuged at 17,000xg for 5 minutes and the pellet of insoluble proteins was discarded. Chloroform/methanol precipitation was performed with 2 mg of lysate to remove Triton. Samples were then reduced, alkylated, digested with trypsin, and desalted using Pierce Peptide Desalting Columns following the manufacturer’s protocol. Phosphopeptides were enriched with a High Select Fe-NTA Phosphopeptide Enrichment Kit (Thermo Scientific) according to the manufacturer’s protocol. The enriched peptides were dried with a vacuum centrifuge. Dried peptides were resuspended in 0.15% formic acid in HPLC Water and loaded onto a Vanquish Neo UHPLC system (Thermo Fisher Scientific) with a heated trap and elute workflow containing a c18 PrepMap, 5mm, trap column (cat #160454) with a forward-flush configuration connected to a 25cm Easyspray analytical column (cat #ES802A rev2), 2u,100A, 75um × 25 of 100% Buffer A (0.1% formic acid in water) and a column oven set to 40 °C. Peptides were eluted over a 150 min gradient using 80% acetonitrile and 0.1% formic acid (buffer B), going from 4% to 5% (5 min), to 35% (125 min), and then to 99% (20 min), after which all peptides were eluted. Spectra were acquired with an Orbitrap Eclipse Tribrid mass spectrometer with FAIMS Pro interface (Thermo Fisher Scientific) running Tune 3.5 and Xcalibur 4.5. For all acquisition methods, spray voltage was set to 1600V, and ion transfer tube temperature was set to 300°C. FAIMS switched between CVs of −45 V, – 55 V, and −65 V with cycle times of 1.5sec. MS1 spectra were acquired at 120,000 resolutions, with a scan range from 375 to 1600 m/z, normalized AGC target of 300%, and maximum injection time of 50ms. S-lens RF level was set to 30. Precursors were filtered using monoisotopic peak determination set to peptide. DDMS2 scan was used in isolation mode Quadrupole, Isolation Window (m/z): 1.6; activation type set to HCD with 30% Collision Energy (CE), orbitrap was set as a detector with resolution of 30K, AGC target was set to 50,000; maximum injection time was set to 54ms, micro scans: 1 and datatype was set to Centroid.
Phosphoproteomic data were analyzed using Proteome Discoverer 2.5 (Thermo Fisher Scientific) using Sequest HT search engines. Mouse Uniprot protein sequence database (uniprot-proteome_UP000000589) was used to generate search parameters that included precursor mass tolerance of 10 ppm and 0.02 Da for fragments, allowing two missed trypsin cleavages, oxidation (Met) and acetylation (protein N-terminus), and phosphorylation (Ser, Thr, and Tyr) as variable modifications, and carbamidomethylation (Cys) as a static modification. Percolator PSM validation was used with the following parameters: strict false discover rate (FDR) of 0.01, relaxed FDR of 0.05, maximum ΔCn of 0.05, and validation based on q-value. Precursor Ions Quantifier settings were to use Unique + Razor for peptides. Precursor abundance was based on intensity, normalization was based on total peptide amount, protein abundance was calculated by the summed intensity of connected peptides, and protein ratios were calculated based on protein abundance.
Metabolomics Studies
Metabolomic analysis was performed by Metabolon, Inc. Briefly, heart samples were immediately snap-frozen in liquid nitrogen and shipped overnight on dry ice to the Metabolon, Inc. Samples were prepared using the automated MicroLab STAR
system from Hamilton Company. Several recovery standards were added prior to the first step in the extraction process for QC purposes. To isolate proteins, small molecules bound to proteins or trapped in the precipitated protein matrix were dissociated. To recover chemically diverse metabolites on these complexes, proteins were precipitated with methanol under vigorous shaking for 2 min (Glen Mills GenoGrinder 2000), followed by centrifugation. The resulting extract was divided into five fractions: two for analysis by two separate reverse phases/UPLC-MS/MS methods with positive ion mode electrospray ionization (ESI), one sample for analysis by RP/UPLC-MS/MS with negative ion mode ESI, one fraction for analysis by HILIC/UPLC-MS/MS with negative ion mode ESI, and one sample was reserved for backup. Samples were placed briefly on a TurboVap
(Zymark) to remove the organic solvent. The sample extracts were stored overnight under nitrogen before preparation for analysis.
Several types of controls were analyzed in concert with the experimental samples: a pooled matrix sample generated by taking a small volume of each experimental sample as a technical replicate of the data set; extracted water samples as process blanks; and a cocktail of QC standards, chosen so as to not interfere with the measurement of endogenous compounds, were spiked into every analyzed sample. These controls allowed for optimal instrument performance monitoring and aided the chromatographic alignment. Instrument variability was determined by calculating the median relative standard deviation (RSD) for the standards that were added to each sample prior to injection into the mass spectrometer. Overall process variability was determined by calculating the median RSD for all endogenous metabolites (non-instrument standards) present in 100% of the pooled matrix samples. Experimental samples were randomized across the platform run with QC samples spaced evenly among the injections.
Peaks were quantified using the area-under-the-curve. For studies spanning multiple days, a data normalization step was performed to correct variation resulting from instrument inter-day tuning differences. Briefly, each compound was corrected in run-day blocks by registering the medians to equal one (1.00) and normalizing each data point proportionately (termed the “block correction”). For studies that did not require more than one day of analysis, no normalization was necessary, other than for purposes of data visualization. In certain instances, biochemical data may have been normalized to an additional factor (such as cell counts, total protein as determined by Bradford assay, osmolality, and so on) to account for differences in metabolite levels due to differences in the amount of material present in each sample.
NAD
and NADH Measurements
NAD
and NADH were measured using the EnzyChrom
NAD
/NADH Assay Kit according to the manufacturer’s protocol (ECND-100, Bioassay Systems, Hayward, CA). Briefly, 20mg of fresh heart tissue was weighed out for each sample and washed with cold PBS. Samples were homogenized in a 1.5mL Eppendorf tube with either 100 μL NAD extraction buffer for NAD determination or 100 μL NADH extraction buffer for NAD determination. Extracts were heated at 60°C for 5 min and neutralized by addition of 20 μL Assay Buffer and 100 μL of Neutralizing Buffer. Samples were vortexed and spun down at 14,000 rpm for 5 min. Supernatants were then collected and used for the NAD/NADH assay. Here, 40 mL of the supernatant was added to 80 mL of the Working Reagent and optical density at 565nm was read at time zero and after a 15-min incubation at room temperature.
Statistical Analysis
All values in graphs are expressed as means ± SEM. Simple group comparisons were performed with the student’s t-test. Longitudinally measured variables were analyzed using two-way repeated measures ANOVA, followed by post-hoc pairwise comparisons performed in conjunction with a Bonferroni correction (GraphPad Prism 9). Diagnostic tools were used to assess model assumptions. A nominal significance level of 0.05 was used throughout. For metabolomics data, to account for the multiple testing, the False Discovery Rate (FDR) method was used with the threshold for computed q-values being set at 0.05
159
Supplementary Material
data file S1
NIHMS2107418-supplement-data_file_S1.xlsx
(21.3KB, xlsx)
MDAR Checklist
NIHMS2107418-supplement-MDAR_Checklist.docx
(68.7KB, docx)
main supplementary
NIHMS2107418-supplement-main_supplementary.docx
(3.2MB, docx)
Figs. S1
S10
Tables S1
S20
Data File S1
Acknowledgments
We would like to thank Dr. Benjamin G. Neel (NYU Grossman School of Medicine, Laura and Isaac Perlmutter Cancer Center, New York) for his generous support in providing the
PTP1B
fl/fl
mice for these studies. Thank you to Dr. Bing Xu for his guidance on isolating primary adult cardiomyocytes. Special thanks as well to Dr. Coralie Poizat for her careful reading of our manuscript. Finally, thanks to the analytical and technical services at the State University of New York (SUNY) College of Environmental Science and Forestry for providing us the transmitted electron microscope data on our mouse hearts.
Figures 7
and
S7
were created using
BioRender.com
Funding
This work was supported by the National Institutes of Health (Grants R01-HL122238, R01-HL102368), the Department of Defense Lupus Impact Award (W81XWH2110784) the American Heart Association Transformation Grant Awards (20TPA35490426, 23TPA1065811), the Lupus and Allied Diseases, Inc., and the Masonic Medical Research Institute to M.I.K.; and by the Halfond-Weil Postdoctoral fellowship to Y.S.
Footnotes
Competing interests
The authors declare that they have no competing interests.
Data and Materials Availability
The mass spectrometry proteomics data was uploaded to the MassIVE repository (
ftp://massive-ftp.ucsd.edu/v09/MSV000097436/
). The metabolomics data have been deposited to the
Metabolights
repository with the dataset identifier MTBLS977. All other data needed to evaluate the conclusions in the paper are present in the paper or the
Supplementary Materials
. The
α-MHC-Cre
mice are available from E.D.A. under a material transfer agreement with the University of Utah.
References and Notes
1.
Ward ZJ, Bleich SN, Cradock AL, Barrett JL, Giles CM, Flax C, Long MW and Gortmaker SL. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. New England Journal of Medicine. 2019;381:2440–2450.
DOI
] [
PubMed
] [
Google Scholar
2.
Chawla A, Chawla R and Jaggi S. Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum?
Indian journal of endocrinology and metabolism. 2016;20:546–51.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
3.
Lavie Carl J, McAuley Paul A, Church Timothy S, Milani Richard V and Blair Steven N. Obesity and Cardiovascular Diseases. Journal of the American College of Cardiology. 2014;63:1345–1354.
DOI
] [
PubMed
] [
Google Scholar
4.
Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV and Ventura HO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail. 2013;1:93–102.
DOI
] [
PubMed
] [
Google Scholar
5.
Cersosimo E and DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev. 2006;22:423–36.
DOI
] [
PubMed
] [
Google Scholar
6.
Kolwicz SC Jr., Purohit S and Tian R. Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circulation research. 2013;113:603–16.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
7.
Stanley WC, Recchia FA and Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiological reviews. 2005;85:1093–129.
DOI
] [
PubMed
] [
Google Scholar
8.
Tran DH and Wang ZV. Glucose Metabolism in Cardiac Hypertrophy and Heart Failure. Journal of the American Heart Association. 2019;8:e012673.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
9.
Lopaschuk GD, Karwi QG, Tian R, Wende AR and Abel ED. Cardiac Energy Metabolism in Heart Failure. Circulation research. 2021;128:1487–1513.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
10.
Sithara T and Drosatos K. Metabolic Complications in Cardiac Aging. Front Physiol. 2021;12:669497.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
11.
Azevedo PS, Minicucci MF, Santos PP, Paiva SA and Zornoff LA. Energy metabolism in cardiac remodeling and heart failure. Cardiology in review. 2013;21:135–40.
DOI
] [
PubMed
] [
Google Scholar
12.
Goldberg IJ, Trent CM and Schulze PC. Lipid metabolism and toxicity in the heart. Cell metabolism. 2012;15:805–12.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
13.
Szczepaniak LS, Dobbins RL, Metzger GJ, Sartoni-D’Ambrosia G, Arbique D, Vongpatanasin W, Unger R and Victor RG. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magnetic resonance in medicine. 2003;49:417–23.
DOI
] [
PubMed
] [
Google Scholar
14.
Fukushima A and Lopaschuk GD. Cardiac fatty acid oxidation in heart failure associated with obesity and diabetes. Biochimica et biophysica acta. 2016;1861:1525–34.
DOI
] [
PubMed
] [
Google Scholar
15.
Virkamäki A, Ueki K and Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. The Journal of clinical investigation. 1999;103:931–43.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
16.
Beith JL, Alejandro EU and Johnson JD. Insulin stimulates primary beta-cell proliferation via Raf-1 kinase. Endocrinology. 2008;149:2251–60.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
17.
Porras A and Santos E. The insulin/Ras pathway of adipocytic differentiation of 3T3 L1 cells: dissociation between Raf-1 kinase and the MAPK/RSK cascade. Int J Obes Relat Metab Disord. 1996;20
Suppl 3:S43–51.
PubMed
] [
Google Scholar
18.
Gezginci-Oktayoglu S, Karatug A and Bolkent S. The relation among NGF, EGF and insulin is important for triggering pancreatic β cell apoptosis. Diabetes Metab Res Rev. 2012;28:654–62.
DOI
] [
PubMed
] [
Google Scholar
19.
Yang Q, Vijayakumar A and Kahn BB. Metabolites as regulators of insulin sensitivity and metabolism. Nature reviews Molecular cell biology. 2018;19:654–672.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
20.
Haeusler RA, McGraw TE and Accili D. Biochemical and cellular properties of insulin receptor signalling. Nature Reviews Molecular Cell Biology. 2018;19:31–44.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
21.
Taniguchi CM, Emanuelli B and Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nature Reviews Molecular Cell Biology. 2006;7:85–96.
DOI
] [
PubMed
] [
Google Scholar
22.
Chernoff J
Protein tyrosine phosphatases as negative regulators of mitogenic signaling. Journal of cellular physiology. 1999;180:173–81.
DOI
] [
PubMed
] [
Google Scholar
23.
Delibegovic M, Zimmer D, Kauffman C, Rak K, Hong EG, Cho YR, Kim JK, Kahn BB, Neel BG and Bence KK. Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress. Diabetes. 2009;58:590–9.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
24.
Simoncic PD, McGlade CJ and Tremblay ML. PTP1B and TC-PTP: novel roles in immune-cell signaling. Canadian journal of physiology and pharmacology. 2006;84:667–75.
DOI
] [
PubMed
] [
Google Scholar
25.
Goldstein BJ, Ahmad F, Ding W, Li PM and Zhang WR. Regulation of the insulin signalling pathway by cellular protein-tyrosine phosphatases. Molecular and cellular biochemistry. 1998;182:91–9.
PubMed
] [
Google Scholar
26.
Ahmad F and Goldstein BJ. Increased abundance of specific skeletal muscle protein-tyrosine phosphatases in a genetic model of insulin-resistant obesity and diabetes mellitus. Metabolism. 1995;44:1175–1184.
DOI
] [
PubMed
] [
Google Scholar
27.
Ahmad F and Goldstein BJ. Alterations in specific protein-tyrosine phosphatases accompany insulin resistance of streptozotocin diabetes. American Journal of Physiology-Endocrinology And Metabolism. 1995;268:E932–E940.
DOI
] [
PubMed
] [
Google Scholar
28.
Dadke SS, Li HC, Kusari AB, Begum N and Kusari J. Elevated expression and activity of protein-tyrosine phosphatase 1B in skeletal muscle of insulin-resistant type II diabetic Goto-Kakizaki rats. Biochemical and biophysical research communications. 2000;274:583–589.
DOI
] [
PubMed
] [
Google Scholar
29.
Wu Y, Ouyang JP, Wu K, Wang SS, Wen CY and Xia ZY. Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat-fed, streptozotocin-treated diabetic rats. British journal of pharmacology. 2005;146:234–243.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
30.
Lam N, Covey S, Lewis J, Oosman S, Webber T, Hsu E, Cheung A and Kieffer T. Leptin resistance following over-expression of protein tyrosine phosphatase 1B in liver. Journal of Molecular Endocrinology. 2006;36:163–174.
DOI
] [
PubMed
] [
Google Scholar
31.
Ahmad F, Azevedo J, Cortright R, Dohm GL and Goldstein BJ. Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. The Journal of clinical investigation. 1997;100:449–458.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
32.
Ahmad F, Considine RV, Bauer TL, Ohannesian JP, Marco CC and Goldstein BJ. Improved sensitivity to insulin in obese subjects following weight loss is accompanied by reduced protein-tyrosine phosphatases in adipose tissue. Metabolism. 1997;46:1140–1145.
DOI
] [
PubMed
] [
Google Scholar
33.
Cheung A, Kusari J, Jansen D, Bandyopadhyay D, Kusari A and Bryer-Ash M. Marked impairment of protein tyrosine phosphatase 1B activity in adipose tissue of obese subjects with and without type 2 diabetes mellitus. Journal of Laboratory and Clinical Medicine. 1999;134:115–123.
DOI
] [
PubMed
] [
Google Scholar
34.
Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, Normandin D, Cheng A, Himms-Hagen J, Chan CC, Ramachandran C, Gresser MJ, Tremblay ML and Kennedy BP. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science. 1999;283:1544–8.
DOI
] [
PubMed
] [
Google Scholar
35.
Bettaieb A, Bakke J, Nagata N, Matsuo K, Xi Y, Liu S, AbouBechara D, Melhem R, Stanhope K, Cummings B, Graham J, Bremer A, Zhang S, Lyssiotis CA, Zhang ZY, Cantley LC, Havel PJ and Haj FG. Protein tyrosine phosphatase 1B regulates pyruvate kinase M2 tyrosine phosphorylation. The Journal of biological chemistry. 2013;288:17360–71.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
36.
Bence KK, Delibegovic M, Xue B, Gorgun CZ, Hotamisligil GS, Neel BG and Kahn BB. Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat Med. 2006;12:917–24.
DOI
] [
PubMed
] [
Google Scholar
37.
De Jonghe BC, Hayes MR, Banno R, Skibicka KP, Zimmer DJ, Bowen KA, Leichner TM, Alhadeff AL, Kanoski SE, Cyr NE, Nillni EA, Grill HJ and Bence KK. Deficiency of PTP1B in POMC neurons leads to alterations in energy balance and homeostatic response to cold exposure. American journal of physiology Endocrinology and metabolism. 2011;300:E1002–11.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
38.
Xu Q, Wu N, Li X, Guo C, Li C, Jiang B, Wang H and Shi D. Inhibition of PTP1B blocks pancreatic cancer progression by targeting the PKM2/AMPK/mTOC1 pathway. Cell Death & Disease. 2019;10:874.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
39.
Sanders MJ, Grondin PO, Hegarty BD, Snowden MA and Carling D. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. The Biochemical journal. 2007;403:139–48.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
40.
Munday MR, Campbell DG, Carling D and Hardie DG. Identification by amino acid sequencing of three major regulatory phosphorylation sites on rat acetyl-CoA carboxylase. European journal of biochemistry. 1988;175:331–8.
DOI
] [
PubMed
] [
Google Scholar
41.
Dzamko NL and Steinberg GR. AMPK-dependent hormonal regulation of whole-body energy metabolism. Acta physiologica (Oxford, England). 2009;196:115–27.
DOI
] [
PubMed
] [
Google Scholar
42.
O’Neill HM, Holloway GP and Steinberg GR. AMPK regulation of fatty acid metabolism and mitochondrial biogenesis: implications for obesity. Molecular and cellular endocrinology. 2013;366:135–51.
DOI
] [
PubMed
] [
Google Scholar
43.
Fulco M, Cen Y, Zhao P, Hoffman EP, McBurney MW, Sauve AA and Sartorelli V. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Developmental cell. 2008;14:661–73.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
44.
Hsu CP, Oka S, Shao D, Hariharan N and Sadoshima J. Nicotinamide phosphoribosyltransferase regulates cell survival through NAD+ synthesis in cardiac myocytes. Circulation research. 2009;105:481–91.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
45.
Nguyen TD, Schwarzer M, Schrepper A, Amorim PA, Blum D, Hain C, Faerber G, Haendeler J, Altschmied J and Doenst T. Increased Protein Tyrosine Phosphatase 1B (PTP1B) Activity and Cardiac Insulin Resistance Precede Mitochondrial and Contractile Dysfunction in Pressure-Overloaded Hearts. Journal of the American Heart Association. 2018;7.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
46.
Fang CX, Doser TA, Yang X, Sreejayan N and Ren J. Metallothionein antagonizes aging-induced cardiac contractile dysfunction: role of PTP1B, insulin receptor tyrosine phosphorylation and Akt. Aging Cell. 2006;5:177–185.
DOI
] [
PubMed
] [
Google Scholar
47.
Gogiraju R, Schroeter MR, Bochenek ML, Hubert A, Münzel T, Hasenfuss G and Schäfer K. Endothelial deletion of protein tyrosine phosphatase-1B protects against pressure overload-induced heart failure in mice. Cardiovascular research. 2016;111:204–16.
DOI
] [
PubMed
] [
Google Scholar
48.
Lanahan AA, Lech D, Dubrac A, Zhang J, Zhuang ZW, Eichmann A and Simons M. PTP1b Is a Physiologic Regulator of Vascular Endothelial Growth Factor Signaling in Endothelial Cells. Circulation. 2014;130:902–909.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
49.
Gupte M, Thatcher SE, Boustany-Kari CM, Shoemaker R, Yiannikouris F, Zhang X, Karounos M and Cassis LA. Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice. Arterioscler Thromb Vasc Biol. 2012;32:1392–9.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
50.
Pettersson US, Waldén TB, Carlsson PO, Jansson L and Phillipson M. Female mice are protected against high-fat diet induced metabolic syndrome and increase the regulatory T cell population in adipose tissue. PLoS One. 2012;7:e46057.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
51.
Ganz M, Csak T and Szabo G. High fat diet feeding results in gender specific steatohepatitis and inflammasome activation. World J Gastroenterol. 2014;20:8525–34.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
52.
Singer K, Maley N, Mergian T, DelProposto J, Cho KW, Zamarron BF, Martinez-Santibanez G, Geletka L, Muir L, Wachowiak P, Demirjian C and Lumeng CN. Differences in Hematopoietic Stem Cells Contribute to Sexually Dimorphic Inflammatory Responses to High Fat Diet-induced Obesity. The Journal of biological chemistry. 2015;290:13250–62.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
53.
Tong D, Schiattarella GG, Jiang N, May HI, Lavandero S, Gillette TG and Hill JA. Female Sex Is Protective in a Preclinical Model of Heart Failure With Preserved Ejection Fraction. Circulation. 2019;140:1769–1771.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
54.
Oraha J, Enriquez RF, Herzog H and Lee NJ. Sex-specific changes in metabolism during the transition from chow to high-fat diet feeding are abolished in response to dieting in C57BL/6J mice. International Journal of Obesity. 2022;46:1749–1758.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
55.
Lu Y, Lu X, Wang L and Yang W. Resveratrol attenuates high fat diet-induced mouse cardiomyopathy through upregulation of estrogen related receptor-α. European Journal of Pharmacology. 2019;843:88–95.
DOI
] [
PubMed
] [
Google Scholar
56.
Chen F, Yu H, Zhang H, Zhao R, Cao K, Liu Y, Luo J and Xue Q. Estrogen normalizes maternal HFD-induced cardiac hypertrophy in offspring by regulating AT2R. Journal of Endocrinology. 2021;250:1–12.
DOI
] [
PubMed
] [
Google Scholar
57.
Regitz-Zagrosek V and Kararigas G. Mechanistic Pathways of Sex Differences in Cardiovascular Disease. Physiological reviews. 2017;97:1–37.
DOI
] [
PubMed
] [
Google Scholar
58.
Bhan A, Sirker A, Zhang J, Protti A, Catibog N, Driver W, Botnar R, Monaghan MJ and Shah AM. High-frequency speckle tracking echocardiography in the assessment of left ventricular function and remodeling after murine myocardial infarction. American Journal of Physiology-Heart and Circulatory Physiology. 2014;306:H1371–H1383.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
59.
Mondillo S, Galderisi M, Mele D, Cameli M, Lomoriello VS, Zacà V, Ballo P, D’Andrea A, Muraru D, Losi M, Agricola E, D’Errico A, Buralli S, Sciomer S, Nistri S and Badano L. Speckle-tracking echocardiography: a new technique for assessing myocardial function. J Ultrasound Med. 2011;30:71–83.
DOI
] [
PubMed
] [
Google Scholar
60.
Nguyen S, Shao D, Tomasi LC, Braun A, de Mattos ABM, Choi YS, Villet O, Roe N, Halterman CR, Tian R and Kolwicz SC. The effects of fatty acid composition on cardiac hypertrophy and function in mouse models of diet-induced obesity. The Journal of Nutritional Biochemistry. 2017;46:137–142.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
61.
Shao D, Kolwicz SC, Wang P, Roe ND, Villet O, Nishi K, Hsu Y-WA, Flint GV, Caudal A, Wang W, Regnier M and Tian R. Increasing Fatty Acid Oxidation Prevents High-Fat Diet–Induced Cardiomyopathy Through Regulating Parkin-Mediated Mitophagy. Circulation. 2020;142:983–997.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
62.
Schrauwen P, Schrauwen-Hinderling V, Hoeks J and Hesselink MK. Mitochondrial dysfunction and lipotoxicity. Biochimica et biophysica acta. 2010;1801:266–71.
DOI
] [
PubMed
] [
Google Scholar
63.
Ritterhoff J and Tian R. Metabolism in cardiomyopathy: every substrate matters. Cardiovascular research. 2017;113:411–421.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
64.
Zeng H, Vaka VR, He X, Booz GW and Chen J-X. High-fat diet induces cardiac remodelling and dysfunction: assessment of the role played by SIRT3 loss. Journal of Cellular and Molecular Medicine. 2015;19:1847–1856.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
65.
Byeon HJ, Kim J-Y, Ko J, Lee EJ, Don K and Yoon JS. Protein tyrosine phosphatase 1B as a therapeutic target for Graves’ orbitopathy in an in vitro model. PLOS ONE. 2020;15:e0237015.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
66.
Sohail A, Fayyaz H, Muneer H, Raza I, Ikram M, Uddin Z, Gul S, Almohaimeed HM, Alsharif I, Alaryani FS and Ullah I. Targeted Inhibition of Protein Tyrosine Phosphatase 1B by Viscosol Ameliorates Type 2 Diabetes Pathophysiology and Histology in Diabetic Mouse Model. BioMed Research International. 2022;2022:2323078.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
67.
Pang Z, Zhou G, Ewald J, Chang L, Hacariz O, Basu N and Xia J. Using MetaboAnalyst 5.0 for LC–HRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics data. Nature Protocols. 2022;17:1735–1761.
DOI
] [
PubMed
] [
Google Scholar
68.
Sun W, Liu Q, Leng J, Zheng Y and Li J. The role of Pyruvate Dehydrogenase Complex in cardiovascular diseases. Life sciences. 2015;121:97–103.
DOI
] [
PubMed
] [
Google Scholar
69.
Patel MS, Nemeria NS, Furey W and Jordan F. The pyruvate dehydrogenase complexes: structure-based function and regulation. The Journal of biological chemistry. 2014;289:16615–23.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
70.
Patel MS and Korotchkina LG. Regulation of the pyruvate dehydrogenase complex. Biochemical Society transactions. 2006;34:217–22.
DOI
] [
PubMed
] [
Google Scholar
71.
Ayyappan JP, Lizardo K, Wang S, Yurkow E and Nagajyothi JF. Inhibition of SREBP Improves Cardiac Lipidopathy, Improves Endoplasmic Reticulum Stress, and Modulates Chronic Chagas Cardiomyopathy. Journal of the American Heart Association. 2020;9:e014255.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
72.
Huang T-s, Wu T, Fu X-l, Ren H-l, He X-d, Zheng D-h, Tan J, Shen C-h, Xiong S-j, Qian J, Zou Y, Wan J-h, Ji Y-j, Liu M-y, Wu Y-d, Li X-h, Li H, Zheng K, Yang X-f, Wang H, Ren M and Cai W-b. SREBP1 induction mediates long-term statins therapy related myocardial lipid peroxidation and lipid deposition in TIIDM mice. Redox Biology. 2024;78:103412.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
73.
Finck BN. The PPAR regulatory system in cardiac physiology and disease. Cardiovascular research. 2007;73:269–77.
DOI
] [
PubMed
] [
Google Scholar
74.
Kalliora C and Drosatos K. The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation. J Cardiovasc Pharmacol. 2020;76:514–526.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
75.
Chiarugi P
PTPs versus PTKs: the redox side of the coin. Free Radic Res. 2005;39:353–64.
DOI
] [
PubMed
] [
Google Scholar
76.
Cho H
Protein tyrosine phosphatase 1B (PTP1B) and obesity. Vitamins and hormones. 2013;91:405–24.
DOI
] [
PubMed
] [
Google Scholar
77.
Huang da W, Sherman BT and Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57.
DOI
] [
PubMed
] [
Google Scholar
78.
Walker KS, Watt PW and Cohen P. Phosphorylation of the skeletal muscle glycogen-targetting subunit of protein phosphatase 1 in response to adrenaline in vivo. FEBS Letters. 2000;466:121–124.
DOI
] [
PubMed
] [
Google Scholar
79.
González-Rodríguez Á, Más-Gutierrez JA, Mirasierra M, Fernandez-Pérez A, Lee YJ, Ko HJ, Kim JK, Romanos E, Carrascosa JM and Ros M. Essential role of protein tyrosine phosphatase 1B in obesity-induced inflammation and peripheral insulin resistance during aging. Aging cell. 2012;11:284–296.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
80.
Través PG, Pardo V, Pimentel-Santillana M, González-Rodríguez Á, Mojena M, Rico D, Montenegro Y, Calés C, Martín-Sanz P, Valverde AM and Boscá L. Pivotal role of protein tyrosine phosphatase 1B (PTP1B) in the macrophage response to pro-inflammatory and anti-inflammatory challenge. Cell Death & Disease. 2014;5:e1125–e1125.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
81.
Asante-Appiah E and Kennedy BP. Protein tyrosine phosphatases: the quest for negative regulators of insulin action. American journal of physiology Endocrinology and metabolism. 2003;284:E663–70.
DOI
] [
PubMed
] [
Google Scholar
82.
Kroll J and Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. The Journal of biological chemistry. 1997;272:32521–7.
DOI
] [
PubMed
] [
Google Scholar
83.
Minami T, Horiuchi K, Miura M, Abid MR, Takabe W, Noguchi N, Kohro T, Ge X, Aburatani H, Hamakubo T, Kodama T and Aird WC. Vascular endothelial growth factor- and thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis. The Journal of biological chemistry. 2004;279:50537–54.
DOI
] [
PubMed
] [
Google Scholar
84.
Yang TT, Xiong Q, Enslen H, Davis RJ and Chow CW. Phosphorylation of NFATc4 by p38 mitogen-activated protein kinases. Mol Cell Biol. 2002;22:3892–904.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
85.
Hsu HC, Chen CY, Lee BC and Chen MF. High-fat diet induces cardiomyocyte apoptosis via the inhibition of autophagy. Eur J Nutr. 2016;55:2245–54.
DOI
] [
PubMed
] [
Google Scholar
86.
Qian S, Wei Z, Yang W, Huang J, Yang Y and Wang J. The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Frontiers in Oncology. 2022;12.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
87.
Martin TG, Myers VD, Dubey P, Dubey S, Perez E, Moravec CS, Willis MS, Feldman AM and Kirk JA. Cardiomyocyte contractile impairment in heart failure results from reduced BAG3-mediated sarcomeric protein turnover. Nat Commun. 2021;12:2942.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
88.
Kirk JA, Cheung JY and Feldman AM. Therapeutic targeting of BAG3: considering its complexity in cancer and heart disease. The Journal of clinical investigation. 2021;131.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
89.
Chao DT and Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu Rev Immunol. 1998;16:395–419.
DOI
] [
PubMed
] [
Google Scholar
90.
Lin H, Koren SA, Cvetojevic G, Girardi P and Johnson GVW. The role of BAG3 in health and disease: A “Magic BAG of Tricks”. Journal of Cellular Biochemistry. 2022;123:4–21.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
91.
Wang Y, Fan Y, Song Y, Han X, Fu M, Wang J, Cui X, Cao J, Chen L, Hu K, Sun A, Zhou J and Ge J. Angiotensin II induces apoptosis of cardiac microvascular endothelial cells via regulating PTP1B/PI3K/Akt pathway. In Vitro Cellular & Developmental Biology - Animal. 2019;55:801–811.
DOI
] [
PubMed
] [
Google Scholar
92.
Khamzina L, Veilleux A, Bergeron S and Marette A. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology. 2005;146:1473–81.
DOI
] [
PubMed
] [
Google Scholar
93.
Almouhanna F, Blagojevic B, Can S, Ghanem A and Wölfl S. Pharmacological activation of pyruvate kinase M2 reprograms glycolysis leading to TXNIP depletion and AMPK activation in breast cancer cells. Cancer & Metabolism. 2021;9:5.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
94.
Cantó C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, Elliott PJ, Puigserver P and Auwerx J. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 2009;458:1056–1060.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
95.
Gomez E, Vercauteren M, Kurtz B, Ouvrard-Pascaud A, Mulder P, Henry JP, Besnier M, Waget A, Hooft Van Huijsduijnen R, Tremblay ML, Burcelin R, Thuillez C and Richard V. Reduction of heart failure by pharmacological inhibition or gene deletion of protein tyrosine phosphatase 1B. J Mol Cell Cardiol. 2012;52:1257–64.
DOI
] [
PubMed
] [
Google Scholar
96.
Yan Y, Dang H, Zhang X, Wang X and Liu X. The protective role of MiR-206 in regulating cardiomyocytes apoptosis induced by ischemic injury by targeting PTP1B. Bioscience Reports. 2020;40.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
] [
Retracted
97.
Zhang Y, Li Q, Youn JY and Cai H. Protein Phosphotyrosine Phosphatase 1B (PTP1B) in Calpain-dependent Feedback Regulation of Vascular Endothelial Growth Factor Receptor (VEGFR2) in Endothelial Cells: IMPLICATIONS IN VEGF-DEPENDENT ANGIOGENESIS AND DIABETIC WOUND HEALING. The Journal of biological chemistry. 2017;292:407–416.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
98.
Wang Y, Fan Y, Song Y, Han X, Fu M, Wang J, Cui X, Cao J, Chen L, Hu K, Sun A, Zhou J and Ge J. Angiotensin II induces apoptosis of cardiac microvascular endothelial cells via regulating PTP1B/PI3K/Akt pathway. In vitro cellular & developmental biology Animal. 2019;55:801–811.
DOI
] [
PubMed
] [
Google Scholar
99.
Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, Hewett TE, Jones SP, Lefer DJ, Peng C-F, Kitsis RN and Molkentin JD. The MEK1–ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. The EMBO Journal. 2000;19:6341–6350.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
100.
Mutlak M, Schlesinger-Laufer M, Haas T, Shofti R, Ballan N, Lewis YE, Zuler M, Zohar Y, Caspi LH and Kehat I. Extracellular signal-regulated kinase (ERK) activation preserves cardiac function in pressure overload induced hypertrophy. International Journal of Cardiology. 2018;270:204–213.
DOI
] [
PubMed
] [
Google Scholar
101.
Matsui T, Li L, Wu JC, Cook SA, Nagoshi T, Picard MH, Liao R and Rosenzweig A. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. The Journal of biological chemistry. 2002;277:22896–901.
DOI
] [
PubMed
] [
Google Scholar
102.
Condorelli G, Drusco A, Stassi G, Bellacosa A, Roncarati R, Iaccarino G, Russo MA, Gu Y, Dalton N, Chung C, Latronico MV, Napoli C, Sadoshima J, Croce CM and Ross J Jr. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America. 2002;99:12333–8.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
103.
Shioi T, McMullen JR, Kang PM, Douglas PS, Obata T, Franke TF, Cantley LC and Izumo S. Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol. 2002;22:2799–809.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
104.
Tong M and Sadoshima J. Mitochondrial autophagy in cardiomyopathy. Current opinion in genetics & development. 2016;38:8–15.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
105.
Tong M, Saito T, Zhai P, Oka SI, Mizushima W, Nakamura M, Ikeda S, Shirakabe A and Sadoshima J. Mitophagy Is Essential for Maintaining Cardiac Function During High Fat Diet-Induced Diabetic Cardiomyopathy. Circulation research. 2019;124:1360–1371.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
106.
Shimauchi T, Boucherat O, Yokokawa T, Grobs Y, Wu W, Orcholski M, Martineau S, Omura J, Tremblay E, Shimauchi K, Nadeau V, Breuils-Bonnet S, Paulin R, Potus F, Provencher S and Bonnet S. PARP1-PKM2 Axis Mediates Right Ventricular Failure Associated With Pulmonary Arterial Hypertension. JACC Basic to translational science. 2022;7:384–403.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
107.
Zhang H, Wang D, Li M, Plecitá-Hlavatá L, D’Alessandro A, Tauber J, Riddle S, Kumar S, Flockton A, McKeon BA, Frid MG, Reisz JA, Caruso P, Kasmi KCE, Ježek P, Morrell NW, Hu C-J and Stenmark KR. Metabolic and Proliferative State of Vascular Adventitial Fibroblasts in Pulmonary Hypertension Is Regulated Through a MicroRNA-124/PTBP1 (Polypyrimidine Tract Binding Protein 1)/Pyruvate Kinase Muscle Axis. Circulation. 2017;136:2468–2485.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
108.
Kolwicz SC, Purohit S and Tian R. Cardiac Metabolism and its Interactions With Contraction, Growth, and Survival of Cardiomyocytes. Circulation research. 2013;113:603–616.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
109.
Akki A, Smith K and Seymour AM. Compensated cardiac hypertrophy is characterised by a decline in palmitate oxidation. Molecular and cellular biochemistry. 2008;311:215–24.
DOI
] [
PubMed
] [
Google Scholar
110.
Barger PM and Kelly DP. Fatty acid utilization in the hypertrophied and failing heart: molecular regulatory mechanisms. The American journal of the medical sciences. 1999;318:36–42.
DOI
] [
PubMed
] [
Google Scholar
111.
Kolwicz SC, Olson DP, Marney LC, Garcia-Menendez L, Synovec RE and Tian R. Cardiac-Specific Deletion of Acetyl CoA Carboxylase 2 Prevents Metabolic Remodeling During Pressure-Overload Hypertrophy. Circulation research. 2012;111:728–738.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
112.
Schiattarella GG, Altamirano F, Kim SY, Tong D, Ferdous A, Piristine H, Dasgupta S, Wang X, French KM, Villalobos E, Spurgin SB, Waldman M, Jiang N, May HI, Hill TM, Luo Y, Yoo H, Zaha VG, Lavandero S, Gillette TG and Hill JA. Xbp1s-FoxO1 axis governs lipid accumulation and contractile performance in heart failure with preserved ejection fraction. Nature Communications. 2021;12:1684.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
113.
Ranjbarvaziri S, Kooiker KB, Ellenberger M, Fajardo G, Zhao M, Vander Roest AS, Woldeyes RA, Koyano TT, Fong R, Ma N, Tian L, Traber GM, Chan F, Perrino J, Reddy S, Chiu W, Wu JC, Woo JY, Ruppel KM, Spudich JA, Snyder MP, Contrepois K and Bernstein D. Altered Cardiac Energetics and Mitochondrial Dysfunction in Hypertrophic Cardiomyopathy. Circulation. 2021;144:1714–1731.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
114.
Coats CJ, Heywood WE, Virasami A, Ashrafi N, Syrris P, Dos Remedios C, Treibel TA, Moon JC, Lopes LR and McGregor CG. Proteomic analysis of the myocardium in hypertrophic obstructive cardiomyopathy. Circulation: Genomic and Precision Medicine. 2018;11:e001974.
DOI
] [
PubMed
] [
Google Scholar
115.
Schuldt M, Pei J, Harakalova M, Dorsch LM, Schlossarek S, Mokry M, Knol JC, Pham TV, Schelfhorst T and Piersma SR. Proteomic and functional studies reveal detyrosinated tubulin as treatment target in sarcomere mutation-induced hypertrophic cardiomyopathy. Circulation: Heart Failure. 2021;14:e007022.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
116.
Mazumder PK, O’Neill BT, Roberts MW, Buchanan J, Yun UJ, Cooksey RC, Boudina S and Abel ED. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes. 2004;53:2366–74.
DOI
] [
PubMed
] [
Google Scholar
117.
Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L and Unger RH. Lipotoxic heart disease in obese rats: implications for human obesity. Proceedings of the National Academy of Sciences of the United States of America. 2000;97:1784–9.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
118.
Olpin SE. Pathophysiology of fatty acid oxidation disorders and resultant phenotypic variability. Journal of inherited metabolic disease. 2013;36:645–58.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
119.
Alhayaza R, Haque E, Karbasiafshar C, Sellke FW and Abid MR. The Relationship Between Reactive Oxygen Species and Endothelial Cell Metabolism. Front Chem. 2020;8:592688.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
120.
Yan A, Xie G, Ding X, Wang Y and Guo L. Effects of Lipid Overload on Heart in Metabolic Diseases. Horm Metab Res. 2021;53:771–778.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
121.
Duncan JG, Bharadwaj KG, Fong JL, Mitra R, Sambandam N, Courtois MR, Lavine KJ, Goldberg IJ and Kelly DP. Rescue of cardiomyopathy in peroxisome proliferator-activated receptor-alpha transgenic mice by deletion of lipoprotein lipase identifies sources of cardiac lipids and peroxisome proliferator-activated receptor-alpha activators. Circulation. 2010;121:426–35.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
122.
Haemmerle G, Lass A, Zimmermann R, Gorkiewicz G, Meyer C, Rozman J, Heldmaier G, Maier R, Theussl C, Eder S, Kratky D, Wagner EF, Klingenspor M, Hoefler G and Zechner R. Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science. 2006;312:734–7.
DOI
] [
PubMed
] [
Google Scholar
123.
Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O, Bain J, Stevens R, Dyck JR, Newgard CB, Lopaschuk GD and Muoio DM. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell metabolism. 2008;7:45–56.
DOI
] [
PubMed
] [
Google Scholar
124.
Steffen LM, Vessby B, Jacobs DR, Steinberger J, Moran A, Hong CP and Sinaiko AR. Serum phospholipid and cholesteryl ester fatty acids and estimated desaturase activities are related to overweight and cardiovascular risk factors in adolescents. International Journal of Obesity. 2008;32:1297–1304.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
125.
Pulinilkunnil T and Rodrigues B. Cardiac lipoprotein lipase: Metabolic basis for diabetic heart disease. Cardiovascular research. 2006;69:329–340.
DOI
] [
PubMed
] [
Google Scholar
126.
Wang B and Tontonoz P. Phospholipid Remodeling in Physiology and Disease. Annu Rev Physiol. 2019;81:165–188.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
127.
Wajner M and Amaral AU. Mitochondrial dysfunction in fatty acid oxidation disorders: insights from human and animal studies. Biosci Rep. 2015;36:e00281.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
128.
Hadrava Vanova K, Kraus M, Neuzil J and Rohlena J. Mitochondrial complex II and reactive oxygen species in disease and therapy. Redox report : communications in free radical research. 2020;25:26–32.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
129.
Lebiedzinska M, Karkucinska-Wieckowska A, Giorgi C, Karczmarewicz E, Pronicka E, Pinton P, Duszynski J, Pronicki M and Wieckowski MR. Oxidative stress-dependent p66Shc phosphorylation in skin fibroblasts of children with mitochondrial disorders. Biochimica et biophysica acta. 2010;1797:952–60.
DOI
] [
PubMed
] [
Google Scholar
130.
Suski JM, Lebiedzinska M, Bonora M, Pinton P, Duszynski J and Wieckowski MR. Relation between mitochondrial membrane potential and ROS formation. Methods in molecular biology (Clifton, NJ). 2012;810:183–205.
DOI
] [
PubMed
] [
Google Scholar
131.
Kolwicz SC Jr., Olson DP, Marney LC, Garcia-Menendez L, Synovec RE and Tian R. Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy. Circ Res. 2012;111:728–38.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
132.
Lembertas AV, Pérusse L, Chagnon YC, Fisler JS, Warden CH, Purcell-Huynh DA, Dionne FT, Gagnon J, Nadeau A, Lusis AJ and Bouchard C. Identification of an obesity quantitative trait locus on mouse chromosome 2 and evidence of linkage to body fat and insulin on the human homologous region 20q. The Journal of clinical investigation. 1997;100:1240–1247.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
133.
Ghosh S, Watanabe RM, Hauser ER, Valle T, Magnuson VL, Erdos MR, Langefeld CD, Balow J, Ally DS, Kohtamaki K, Chines P, Birznieks G, Kaleta H-S, Musick A, Te C, Tannenbaum J, Eldridge W, Shapiro S, Martin C, Witt A, So A, Chang J, Shurtleff B, Porter R, Kudelko K, Unni A, Segal L, Sharaf R, Blaschak-Harvan J, Eriksson J, Tenkula T, Vidgren G, Ehnholm C, Tuomilehto-Wolf E, Hagopian W, Buchanan TA, Tuomilehto J, Bergman RN, Collins FS and Boehnke M. Type 2 diabetes: Evidence for linkage on chromosome 20 in 716 Finnish affected sib pairs. Proceedings of the National Academy of Sciences. 1999;96:2198–2203.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
134.
Lee JH, Reed DR, Li W-D, Xu W, Joo E-J, Kilker RL, Nanthakumar E, North M, Sakul H and Bell C. Genome scan for human obesity and linkage to markers in 20q13. The American Journal of Human Genetics. 1999;64:196–209.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
135.
Brown-Shimer S, Johnson KA, Lawrence JB, Johnson C, Bruskin A, Green NR and Hill DE. Molecular cloning and chromosome mapping of the human gene encoding protein phosphotyrosyl phosphatase 1B. Proceedings of the National Academy of Sciences. 1990;87:5148–5152.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
136.
Echwald SM, Bach H, Vestergaard H, Richelsen B, Kristensen K, Drivsholm T, Borch-Johnsen K, Hansen T and Pedersen O. A P387L Variant in Protein Tyrosine Phosphatase-1B (PTP-1B) Is Associated With Type 2 Diabetes and Impaired Serine Phosphorylation of PTP-1B In Vitro. Diabetes. 2002;51:1–6.
DOI
] [
PubMed
] [
Google Scholar
137.
Mok A, Cao H, Zinman B, Hanley AJG, Harris SB, Kennedy BP and Hegele RA. A Single Nucleotide Polymorphism in Protein Tyrosine Phosphatase PTP-1B Is Associated with Protection from Diabetes or Impaired Glucose Tolerance in Oji-Cree. The Journal of Clinical Endocrinology & Metabolism. 2002;87:724–727.
DOI
] [
PubMed
] [
Google Scholar
138.
Di Paola R, Frittitta L, Miscio G, Bozzali M, Baratta R, Centra M, Spampinato D, Santagati MG, Ercolino T, Cisternino C, Soccio T, Mastroianno S, Tassi V, Almgren P, Pizzuti A, Vigneri R and Trischitta V. A Variation in 3′; UTR of hPTP1B Increases Specific Gene Expression and Associates with Insulin Resistance. The American Journal of Human Genetics. 2002;70:806–812.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
139.
Yamakage H, Konishi Y, Muranaka K, Hotta K, Miyamoto Y, Morisaki H, Morisaki T and Satoh-Asahara N. Association of protein tyrosine phosphatase 1B gene polymorphism with the effects of weight reduction therapy on bodyweight and glycolipid profiles in obese patients. J Diabetes Investig. 2021;12:1462–1470.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
140.
Tsou RC and Bence KK. The Genetics of PTPN1 and Obesity: Insights from Mouse Models of Tissue-Specific PTP1B Deficiency. Journal of Obesity. 2012;2012:926857.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
141.
Oka SI, Byun J, Huang CY, Imai N, Ralda G, Zhai P, Xu X, Kashyap S, Warren JS, Alan Maschek J, Tippetts TS, Tong M, Venkatesh S, Ikeda Y, Mizushima W, Kashihara T and Sadoshima J. Nampt Potentiates Antioxidant Defense in Diabetic Cardiomyopathy. Circulation research. 2021;129:114–130.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
142.
Tong D, Schiattarella GG, Jiang N, Altamirano F, Szweda PA, Elnwasany A, Lee DI, Yoo H, Kass DA, Szweda LI, Lavandero S, Verdin E, Gillette TG and Hill JA. NAD+ Repletion Reverses Heart Failure With Preserved Ejection Fraction. Circulation research. 2021;128:1629–1641.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
143.
Chiao YA, Chakraborty AD, Light CM, Tian R, Sadoshima J, Shi X, Gu H and Lee CF. NAD+ Redox Imbalance in the Heart Exacerbates Diabetic Cardiomyopathy. Circulation: Heart Failure. 2021;14:e008170.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
144.
Zhou L, Zhang S, Bolor-Erdene E, Wang L, Tian D and Mei Y. NAMPT/SIRT1 Attenuate Ang II-Induced Vascular Remodeling and Vulnerability to Hypertension by Inhibiting the ROS/MAPK Pathway. Oxidative Medicine and Cellular Longevity. 2020;2020:1974265.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
145.
Lan F, Weikel KA, Cacicedo JM and Ido Y. Resveratrol-Induced AMP-Activated Protein Kinase Activation Is Cell-Type Dependent: Lessons from Basic Research for Clinical Application. Nutrients. 2017;9:751.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
146.
Liao X, Huang X, Li X, Qiu X, Li M, Liu R, He T and Tang Q. AMPK phosphorylates NAMPT to regulate NAD+ homeostasis under ionizing radiation. Open Biology. 2022;12:220213.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
147.
Yoshino J, Mills KF, Yoon MJ and Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell metabolism. 2011;14:528–36.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
148.
Wu K, Li B, Lin Q, Xu W, Zuo W, Li J, Liu N, Tu T, Zhang B, Xiao Y and Liu Q. Nicotinamide mononucleotide attenuates isoproterenol-induced cardiac fibrosis by regulating oxidative stress and Smad3 acetylation. Life sciences. 2021;274:119299.
DOI
] [
PubMed
] [
Google Scholar
149.
Coulis G, Londhe AD, Sagabala RS, Shi Y, Labbé DP, Bergeron A, Sahadevan P, Nawaito SA, Sahmi F, Josse M, Vinette V, Guertin MC, Karsenty G, Tremblay ML, Tardif JC, Allen BG and Boivin B. Protein tyrosine phosphatase 1B regulates miR-208b-argonaute 2 association and thyroid hormone responsiveness in cardiac hypertrophy. Sci Signal. 2022;15:eabn6875.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
150.
García-Ruiz I, Blanes Ruiz N, Rada P, Pardo V, Ruiz L, Blas-García A, Valdecantos MP, Grau Sanz M, Solís Herruzo JA and Valverde ÁM. Protein tyrosine phosphatase 1b deficiency protects against hepatic fibrosis by modulating nadph oxidases. Redox Biology. 2019;26:101263.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
151.
Ancel CM, Evans MC, Kerbus RI, Wallace EG and Anderson GM. Deletion of PTP1B From Brain Neurons Partly Protects Mice From Diet-Induced Obesity and Minimally Improves Fertility. Endocrinology. 2022;163.
DOI
] [
PubMed
] [
Google Scholar
152.
Zhou Q, Schötterl S, Backes D, Brunner E, Hahn JK, Ionesi E, Aidery P, Sticht C, Labeit S, Kandolf R, Gawaz M and Gramlich M. Inhibition of miR-208b improves cardiac function in titin-based dilated cardiomyopathy. Int J Cardiol. 2017;230:634–641.
DOI
] [
PubMed
] [
Google Scholar
153.
Grueter CE, van Rooij E, Johnson BA, DeLeon SM, Sutherland LB, Qi X, Gautron L, Elmquist JK, Bassel-Duby R and Olson EN. A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell. 2012;149:671–83.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
154.
Gillet L, Guichard S, Essers MC, Rougier JS and Abriel H. Dystrophin and calcium current are decreased in cardiomyocytes expressing Cre enzyme driven by αMHC but not TNT promoter. Scientific reports. 2019;9:19422.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
155.
Byun J, Oka SI, Imai N, Huang CY, Ralda G, Zhai P, Ikeda Y, Ikeda S and Sadoshima J. Both gain and loss of Nampt function promote pressure overload-induced heart failure. Am J Physiol Heart Circ Physiol. 2019;317:H711–h725.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
156.
Abel ED, Kaulbach HC, Tian R, Hopkins JC, Duffy J, Doetschman T, Minnemann T, Boers ME, Hadro E, Oberste-Berghaus C, Quist W, Lowell BB, Ingwall JS and Kahn BB. Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. The Journal of clinical investigation. 1999;104:1703–14.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
157.
Iuso A, Repp B, Biagosch C, Terrile C and Prokisch H. Assessing Mitochondrial Bioenergetics in Isolated Mitochondria from Various Mouse Tissues Using Seahorse XF96 Analyzer. Methods in molecular biology (Clifton, NJ). 2017;1567:217–230.
DOI
] [
PubMed
] [
Google Scholar
158.
Smiley ST, Reers M, Mottola-Hartshorn C, Lin M, Chen A, Smith TW, Steele GD Jr. and Chen LB. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proceedings of the National Academy of Sciences of the United States of America. 1991;88:3671–5.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
159.
Storey JD and Tibshirani R. Statistical significance for genomewide studies. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:9440–5.
DOI
] [
PMC free article
] [
PubMed
] [
Google Scholar
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
data file S1
NIHMS2107418-supplement-data_file_S1.xlsx
(21.3KB, xlsx)
MDAR Checklist
NIHMS2107418-supplement-MDAR_Checklist.docx
(68.7KB, docx)
main supplementary
NIHMS2107418-supplement-main_supplementary.docx
(3.2MB, docx)
Data Availability Statement
The mass spectrometry proteomics data was uploaded to the MassIVE repository (
ftp://massive-ftp.ucsd.edu/v09/MSV000097436/
). The metabolomics data have been deposited to the
Metabolights
repository with the dataset identifier MTBLS977. All other data needed to evaluate the conclusions in the paper are present in the paper or the
Supplementary Materials
. The
α-MHC-Cre
mice are available from E.D.A. under a material transfer agreement with the University of Utah.
ACTIONS
PERMALINK
RESOURCES
Cite
Download .nbib
.nbib
Format:
Add to Collections